Escherichia coli, one of the many
species of bacteria present in the
human gut
Composition and distribution of gut microbiota in
human body
Gut microbiota
Gut microbiota, gut microbiome, or gut flora are the
microorganisms, including bacteria, archaea, fungi, and viruses, that
live in the digestive tracts of animals.[1][2] The gastrointestinal
metagenome is the aggregate of all the genomes of the gut
microbiota.[3][4] The gut is the main location of the human
microbiome.[5] The gut microbiota has broad impacts, including
effects on colonization, resistance to pathogens, maintaining the
intestinal epithelium, metabolizing dietary and pharmaceutical
compounds, controlling immune function, and even behavior
through the gut–brain axis.[4]
The microbial composition of the gut microbiota varies across
regions of the digestive tract. The colon contains the highest
microbial density of any human-associated microbial community
studied so far, representing between 300 and 1000 different species.[6] Bacteria are the largest and to date,
best studied component and 99% of gut bacteria come from about 30 or 40 species.[7] Up to 60% of the dry
mass of feces is bacteria.[8] Over 99% of the bacteria in the gut are anaerobes, but in the cecum, aerobic
bacteria reach high densities.[5] It is estimated that the human gut microbiota have around a hundred times
as many genes as there are in the human genome.
In humans, the gut microbiota has the highest numbers
and species of bacteria compared to other areas of the
body.[9] 
The 
approximate 
number 
of 
bacteria
composing the gut microbiota is about 1013–1014.[10]
In humans, the gut flora is established at birth and
gradually transitions towards a state resembling that of
adults by the age of two,[11] coinciding with the
development 
and 
maturation 
of 
the 
intestinal
epithelium and intestinal mucosal barrier. This barrier is
essential for supporting a symbiotic relationship with
the gut flora while providing protection against
pathogenic organisms.[12][13]
The relationship between some gut microbiota and
humans is not merely commensal (a non-harmful
coexistence), 
but 
rather 
a 
mutualistic
relationship.[5]: 
700  Some human gut microorganisms
benefit the host by fermenting dietary fiber into short-
chain fatty acids (SCFAs), such as acetic acid and butyric acid, which are then absorbed by the host.[9][14]
Intestinal bacteria also play a role in synthesizing vitamin B and vitamin K as well as metabolizing bile
Overview
Candida albicans, a dimorphic
fungus that grows as a yeast in the
gut
acids, sterols, and xenobiotics.[5][14] The systemic importance of the SCFAs and other compounds they
produce are like hormones and the gut flora itself appears to function like an endocrine organ.[14]
Dysregulation of the gut flora has been correlated with a host of inflammatory and autoimmune
conditions.[9][15]
The composition of human gut microbiota changes over time, when the diet changes, and as overall health
changes.[9][15] A systematic review from 2016 examined the preclinical and small human trials that have
been conducted with certain commercially available strains of probiotic bacteria and identified those that
had the most potential to be useful for certain central nervous system disorders.[16]
The microbial composition of the gut microbiota varies across the digestive tract. In the stomach and small
intestine, relatively few species of bacteria are generally present.[6][17] The colon, in contrast, contains the
highest microbial density of any human-associated microbial community studied so far[18] with between
1010 and 1011 cells per gram of intestinal content.[19] These bacteria represent between 300 and 1000
different species.[6][17] However, 99% of the bacteria come from about 30 or 40 species.[7] As a
consequence of their abundance in the intestine, bacteria also make up to 60% of the dry mass of feces.[8]
Fungi, protists, archaea, and viruses are also present in the gut flora, but less is known about their
activities.[20]
Over 99% of the bacteria in the gut are anaerobes, but in the cecum, aerobic bacteria reach high densities.[5]
It is estimated that these gut flora have around a hundred times as many genes in total as there are in the
human genome.[21]
Many species in the gut have not been studied outside of their hosts
because they cannot be cultured.[17][7][22] While there are a small
number of core microbial species shared by most individuals,
populations of microbes can vary widely.[23] Within an individual,
their microbial populations stay fairly constant over time, with some
alterations occurring due to changes in lifestyle, diet and age.[6][24]
The Human Microbiome Project has set out to better describe the
microbiota of the human gut and other body locations.
The four dominant bacterial phyla in the human gut are Bacillota
(Firmicutes), 
Bacteroidota, 
Actinomycetota, 
and
Pseudomonadota.[25] Most bacteria belong to the genera
Bacteroides, Clostridium, Faecalibacterium,[6][7] Eubacterium,
Ruminococcus, Peptococcus, Peptostreptococcus, and Bifidobacterium.[6][7] Other genera, such as
Escherichia and Lactobacillus, are present to a lesser extent.[6] Species from the genus Bacteroides alone
constitute about 30% of all bacteria in the gut, suggesting that this genus is especially important in the
functioning of the host.[17]
Fungal genera that have been detected in the gut include Candida, Saccharomyces, Aspergillus,
Penicillium, Rhodotorula, Trametes, Pleospora, Sclerotinia, Bullera, and Galactomyces, among
others.[26][27] Rhodotorula is most frequently found in individuals with inflammatory bowel disease while
Candida is most frequently found in individuals with hepatitis B cirrhosis and chronic hepatitis B.[26]
Classifications
Archaea constitute another large class of gut flora which are important in the metabolism of the bacterial
products of fermentation.
Industrialization is associated with changes in the microbiota and the reduction of diversity could drive
certain species to extinction; in 2018, researchers proposed a biobank repository of human microbiota.[28]
An enterotype is a classification of living organisms based on its bacteriological ecosystem in the human gut
microbiome not dictated by age, gender, body weight, or national divisions.[29] There are indications that
long-term diet influences enterotype.[30] Three human enterotypes have been proposed,[29][31] but their
value has been questioned.[32]
Due to the high acidity of the stomach, most microorganisms cannot survive there. The main bacteria of the
gastric microbiota belong to five major phyla: Firmicutes, Bacteroidetes, Actinobacteria, Fusobacteriota,
and Proteobacteria. The dominant genera are Prevotella, Streptococcus, Veillonella, Rothia , and
Haemophilus.[33] The interaction between the pre-existing gastric microbiota with the introduction of
H.  pylori may influence disease progression.[33] When there is a presence of H.  pylori it becomes the
dominant of the microbiota.[34]
The small intestine contains a trace amount of microorganisms due to the proximity and influence of the
stomach. Gram-positive cocci and rod-shaped bacteria are the predominant microorganisms found in the
small intestine.[5] However, in the distal portion of the small intestine alkaline conditions support gram-
negative bacteria of the Enterobacteriaceae.[5] The bacterial flora of the small intestine aid in a wide range
of intestinal functions. The bacterial flora provide regulatory signals that enable the development and utility
of the gut. Overgrowth of bacteria in the small intestine can lead to intestinal failure.[36] In addition the large
intestine contains the largest bacterial ecosystem in the human body.[5] About 99% of the large intestine and
feces flora are made up of obligate anaerobes such as Bacteroides and Bifidobacterium.[37] Factors that
disrupt the microorganism population of the large intestine include antibiotics, stress, and parasites.[5]
Bacteria make up most of the flora in the colon[38] and accounts for 60% of fecal nitrogen.[6] This fact
makes feces an ideal source of gut flora for any tests and experiments by extracting the nucleic acid from
fecal specimens, and bacterial 16S rRNA gene sequences are generated with bacterial primers. This form of
testing is also often preferable to more invasive techniques, such as biopsies.
Five phyla dominate the intestinal microbiota: Bacteroidota, Bacillota (Firmicutes), Actinomycetota,
Pseudomonadota, and Verrucomicrobiota  – with Bacteroidota and Bacillota constituting 90% of the
composition.[39] Somewhere between 300[6] and 1000 different species live in the gut,[17] with most
Enterotype
Composition
Bacteriome
Stomach
Intestines
Bacteria commonly found in the human colon[35]
Bacterium
Incidence (%)
Bacteroides fragilis
100
Bacteroides melaninogenicus
100
Bacteroides oralis
100
Enterococcus faecalis
100
Escherichia coli
100
Enterobacter sp.
40–80
Klebsiella sp.
40–80
Bifidobacterium bifidum
30–70
Staphylococcus aureus
30–50
Lactobacillus
20–60
Clostridium perfringens
25–35
Proteus mirabilis
5–55
Clostridium tetani
1–35
Clostridium septicum
5–25
Pseudomonas aeruginosa
3–11
Salmonella enterica
3–7
Faecalibacterium prausnitzii
?common
Peptostreptococcus sp.
?common
Peptococcus sp.
?common
estimates at about 500.[40][41] However, it is probable
that 99% of the bacteria come from about 30 or 40
species, with Faecalibacterium prausnitzii (phylum
firmicutes) being the most common species in healthy
adults.[7][42]
Research suggests that the relationship between gut
flora and humans is not merely commensal (a non-
harmful coexistence), but rather is a mutualistic,
symbiotic relationship.[17] Though people can survive
with no gut flora,[40] the microorganisms perform a
host of useful functions, such as fermenting unused
energy substrates, training the immune system via end
products of metabolism like propionate and acetate,
preventing growth of harmful species, regulating the
development of the gut, producing vitamins for the
host (such as biotin and vitamin K), and producing
hormones to direct the host to store fats.[5] Extensive
modification and imbalances of the gut microbiota and
its microbiome or gene collection are associated with
obesity.[43] However, in certain conditions, some
species are thought to be capable of causing disease
by causing infection or increasing cancer risk for the
host.[6][38]
Fungi and protists also make up a part of the gut flora,
but less is known about their activities.[44]
The human virome is mostly bacteriophages.[45]
There are common patterns of microbiome composition evolution during life.[46] In general, the diversity of
microbiota composition of fecal samples is significantly higher in adults than in children, although
interpersonal differences are higher in children than in adults.[47] Much of the maturation of microbiota into
an adult-like configuration happens during the first three years of life.[47]
Mycobiome
Virome
Variation
Age
As the microbiome composition changes, so does the composition of bacterial proteins produced in the gut.
In adult microbiomes, a high prevalence of enzymes involved in fermentation, methanogenesis and the
metabolism of arginine, glutamate, aspartate and lysine have been found. In contrast, in infant microbiomes
the dominant enzymes are involved in cysteine metabolism and fermentation pathways.[47]
Gut microbiome composition depends on the geographic origin of populations. Variations in a trade-off of
Prevotella, the representation of the urease gene, and the representation of genes encoding glutamate
synthase/degradation or other enzymes involved in amino acids degradation or vitamin biosynthesis show
significant differences between populations from the US, Malawi, or Amerindian origin.[47]
The US population has a high representation of enzymes encoding the degradation of glutamine and
enzymes involved in vitamin and lipoic acid biosynthesis; whereas Malawi and Amerindian populations
have a high representation of enzymes encoding glutamate synthase and they also have an
overrepresentation of α-amylase in their microbiomes. As the US population has a diet richer in fats than
Amerindian or Malawian populations which have a corn-rich diet, the diet is probably the main determinant
of the gut bacterial composition.[47]
Further studies have indicated a large difference in the composition of microbiota between European and
rural African children. The fecal bacteria of children from Florence were compared to that of children from
the small rural village of Boulpon in Burkina Faso. The diet of a typical child living in this village is largely
lacking in fats and animal proteins and rich in polysaccharides and plant proteins. The fecal bacteria of
European children were dominated by Firmicutes and showed a marked reduction in biodiversity, while the
fecal bacteria of the Boulpon children was dominated by Bacteroidetes. The increased biodiversity and
different composition of the gut microbiome in African populations may aid in the digestion of normally
indigestible plant polysaccharides and also may result in a reduced incidence of non-infectious colonic
diseases.[48]
On a smaller scale, it has been shown that sharing numerous common environmental exposures in a family
is a strong determinant of individual microbiome composition. This effect has no genetic influence and it is
consistently observed in culturally different populations.[47]
Malnourished children have less mature and less diverse gut microbiota than healthy children, and changes
in the microbiome associated with nutrient scarcity can in turn be a pathophysiological cause of
malnutrition.[49][50] Malnourished children also typically have more potentially pathogenic gut flora, and
more yeast in their mouths and throats.[51] Altering diet may lead to changes in gut microbiota composition
and diversity.[52]
Researchers with the American Gut Project and Human Microbiome Project found that twelve microbe
families varied in abundance based on the race or ethnicity of the individual. The strength of these
associations is limited by the small sample size: the American Gut Project collected data from 1,375
individuals, 90% of whom were white.[53] The Healthy Life in an Urban Setting (HELIUS) study in
Amsterdam found that those of Dutch ancestry had the highest level of gut microbiota diversity, while those
Geography
Malnourishment
Race and ethnicity
Illustration showing the developmental colonization of gut microbiota
of South Asian and Surinamese descent had the lowest diversity. The study results suggested that
individuals of the same race or ethnicity have more similar microbiomes than individuals of different racial
backgrounds.[53]
As of 2020, at least two studies have demonstrated a link between an individual's socioeconomic status
(SES) and their gut microbiota. A study in Chicago found that individuals in higher SES neighborhoods had
greater microbiota diversity. People from higher SES neighborhoods also had more abundant Bacteroides
bacteria. Similarly, a study of twins in the United Kingdom found that higher SES was also linked with a
greater gut diversity.[53]
The establishment of a gut flora is crucial to the health of an adult, as well as the functioning of the
gastrointestinal tract.[54] In humans, a gut flora similar to an adult's is formed within one to two years of
birth as microbiota are acquired through parent-to-child transmission and transfer from food, water, and
other environmental sources.[55][12]
The traditional view of the gastrointestinal tract of a normal fetus is that it is sterile, although this view has
been challenged in the past few years.[56] Multiple lines of evidence have begun to emerge that suggest
there may be bacteria in the intrauterine environment. In humans, research has shown that microbial
colonization may occur in the fetus[57] with one study showing Lactobacillus and Bifidobacterium species
were present in placental biopsies.[58] Several rodent studies have demonstrated the presence of bacteria in
the amniotic fluid and placenta, as well as in the meconium of babies born by sterile cesarean
section.[59][60] In another study, researchers administered a culture of bacteria orally to pregnant mice, and
detected the bacteria in the offspring, likely resulting from transmission between the digestive tract and
amniotic fluid via the blood stream.[61] However, researchers caution that the source of these intrauterine
bacteria, whether they are alive, and their role, is not yet understood.[62][58]
During birth and rapidly thereafter, bacteria from the mother and the surrounding environment colonize the
infant's gut.[12] The exact sources of bacteria are not fully understood, but may include the birth canal, other
people (parents, siblings, hospital workers), breastmilk, food, and the general environment with which the
infant interacts.[63] Research has shown that the microbiome of babies born vaginally differs significantly
Socioeconomic status
Acquisition in human infants
from that of babies delivered by caesarean section and that vaginally born babies got most of their gut
bacteria from their mother, while the microbiota of babies born by caesarean section had more bacteria
associated with hospital environments.[64]
During the first year of life, the composition of the gut flora is generally simple and changes a great deal
with time and is not the same across individuals.[12] The initial bacterial population are generally facultative
anaerobic organisms; investigators believe that these initial colonizers decrease the oxygen concentration in
the gut, which in turn allows obligately anaerobic bacteria like Bacteroidota, Actinomycetota, and Bacillota
to become established and thrive.[12] Breast-fed babies become dominated by bifidobacteria, possibly due
to the contents of bifidobacterial growth factors in breast milk, and by the fact that breast milk carries
prebiotic components, allowing for healthy bacterial growth.[58][65] Breast milk also contains higher levels
of Immunoglobulin A (IgA) to help with the tolerance and regulation of the baby's immune system.[66] In
contrast, the microbiota of formula-fed infants is more diverse, with high numbers of Enterobacteriaceae,
enterococci, bifidobacteria, Bacteroides, and clostridia.[67]
Caesarean section, antibiotics, and formula feeding may alter the gut microbiome composition.[58] Children
treated with antibiotics have less stable, and less diverse floral communities.[68] Caesarean sections have
been shown to be disruptive to mother-offspring transmission of bacteria, which impacts the overall health
of the offspring by raising risks of disease such as celiac disease, asthma, and type 1 diabetes.[58] This
further evidences the importance of a healthy gut microbiome. Various methods of microbiome restoration
are being explored, typically involving exposing the infant to maternal vaginal contents, and oral
probiotics.[58]
When the study of gut flora began in 1995,[69] it was thought to have three key roles: direct defense against
pathogens, fortification of host defense by its role in developing and maintaining the intestinal epithelium
and inducing antibody production there, and metabolizing otherwise indigestible compounds in food.
Subsequent work discovered its role in training the developing immune system, and yet further work
focused on its role in the gut–brain axis.[70]
The gut flora community plays a direct role in defending against pathogens by fully colonising the space,
making use of all available nutrients, and by secreting compounds known as cytokines that kill or inhibit
unwelcome organisms that would compete for nutrients with it.[71] Different strains of gut bacteria cause
the production of different cytokines. Cytokines are chemical compounds produced by our immune system
for initiating the inflammatory response against infections. Disruption of the gut flora allows competing
organisms like Clostridium difficile to become established that otherwise are kept in abeyance.[71]
In humans, a gut flora similar to an adult's is formed within one to two years of birth.[12] As the gut flora
gets established, the lining of the intestines – the intestinal epithelium and the intestinal mucosal barrier that
it secretes – develop as well, in a way that is tolerant to, and even supportive of, commensalistic
microorganisms to a certain extent and also provides a barrier to pathogenic ones.[12] Specifically, goblet
cells that produce the mucosa proliferate, and the mucosa layer thickens, providing an outside mucosal layer
Functions
Direct inhibition of pathogens
Development of enteric protection and immune system
Microfold cells transfer antigens (Ag)
from the lumen of the gut to gut-
associated lymphoid tissue (GALT)
via transcytosis and present them to
different innate and adaptive immune
cells.
in which "friendly" microorganisms can anchor and feed, and an
inner layer that even these organisms cannot penetrate.[12][13]
Additionally, the development of gut-associated lymphoid tissue
(GALT), which forms part of the intestinal epithelium and which
detects and reacts to pathogens, appears and develops during the
time that the gut flora develops and established.[12] The GALT that
develops is tolerant to gut flora species, but not to other
microorganisms.[12] GALT also normally becomes tolerant to food
to which the infant is exposed, as well as digestive products of
food, and gut flora's metabolites (molecules formed from
metabolism) produced from food.[12]
The human immune system creates cytokines that can drive the
immune system to produce inflammation in order to protect itself,
and that can tamp down the immune response to maintain
homeostasis and allow healing after insult or injury.[12] Different
bacterial species that appear in gut flora have been shown to be able
to drive the immune system to create cytokines selectively; for
example Bacteroides fragilis and some Clostridia species appear to drive an anti-inflammatory response,
while some segmented filamentous bacteria drive the production of inflammatory cytokines.[12][72] Gut
flora can also regulate the production of antibodies by the immune system.[12][73] One function of this
regulation is to cause B cells to class switch to IgA. In most cases B cells need activation from T helper
cells to induce class switching; however, in another pathway, gut flora cause NF-kB signaling by intestinal
epithelial cells which results in further signaling molecules being secreted.[74] These signaling molecules
interact with B cells to induce class switching to IgA.[74] IgA is an important type of antibody that is used in
mucosal environments like the gut. It has been shown that IgA can help diversify the gut community and
helps in getting rid of bacteria that cause inflammatory responses.[75] Ultimately, IgA maintains a healthy
environment between the host and gut bacteria.[75] These cytokines and antibodies can have effects outside
the gut, in the lungs and other tissues.[12]
The immune system can also be altered due to the gut bacteria's ability to produce metabolites that can
affect cells in the immune system. For example short-chain fatty acids (SCFA) can be produced by some
gut bacteria through fermentation.[76] SCFAs stimulate a rapid increase in the production of innate immune
cells like neutrophils, basophils and eosinophils.[76] These cells are part of the innate immune system that
try to limit the spread of infection.
Metabolism
Tryptophan metabolism by human gastrointestinal microbiota ()
This diagram shows the biosynthesis of bioactive compounds (indole and certain other
derivatives) from tryptophan by bacteria in the gut.[77] Indole is produced from tryptophan by
bacteria that express tryptophanase.[77] Clostridium sporogenes metabolizes tryptophan into indole
and subsequently 3-indolepropionic acid (IPA),[78] a highly potent neuroprotective antioxidant that
scavenges hydroxyl radicals.[77][79][80] IPA binds to the pregnane X receptor (PXR) in intestinal
cells, thereby facilitating mucosal homeostasis and barrier function.[77] Following absorption from
the intestine and distribution to the brain, IPA confers a neuroprotective effect against cerebral
ischemia and Alzheimer's disease.[77] Lactobacillaceae (Lactobacillus s.l.) species metabolize
tryptophan into indole-3-aldehyde (I3A) which acts on the aryl hydrocarbon receptor (AhR) in
intestinal immune cells, in turn increasing interleukin-22 (IL-22) production.[77] Indole itself triggers
the secretion of glucagon-like peptide-1 (GLP-1) in intestinal L cells and acts as a ligand for
AhR.[77] Indole can also be metabolized by the liver into indoxyl sulfate, a compound that is toxic
in high concentrations and associated with vascular disease and renal dysfunction.[77] AST-120
(activated charcoal), an intestinal sorbent that is taken by mouth, adsorbs indole, in turn decreasing
the concentration of indoxyl sulfate in blood plasma.[77]
Without
gut flora,
the human
body
would be
unable to
utilize
some 
of
the
undigested carbohydrates it consumes, because some types of gut flora have enzymes that human cells lack
for breaking down certain polysaccharides.[14] Rodents raised in a sterile environment and lacking in gut
flora need to eat 30% more calories just to remain the same weight as their normal counterparts.[14]
Carbohydrates that humans cannot digest without bacterial help include certain starches, fiber,
oligosaccharides, and sugars that the body failed to digest and absorb like lactose in the case of lactose
intolerance and sugar alcohols, mucus produced by the gut, and proteins.[9][14]
Tryptophan
Clostridium
sporogenes
Lacto-
bacilli
Tryptophanase-
expressing
bacteria
IPA
I3A
Indole
Liver
Brain
IPA
I3A
Indole
Indoxyl
sulfate
AST-120
AhR
Intestinal
immune
cells
Intestinal
epithelium
PXR
Mucosal homeostasis:
↓TNF-α
↑Junction protein-
coding mRNAs
L cell
GLP-1
T J
Neuroprotectant:
↓Activation of glial cells and astrocytes
↓4-Hydroxy-2-nonenal levels
↓DNA damage
–Antioxidant
–Inhibits β-amyloid fibril formation
Maintains mucosal reactivity:
↑IL-22 production
Associated with vascular
disease:
↑Oxidative stress
↑Smooth muscle cell
proliferation
↑Aortic wall thickness and
calcification
Associated with chronic
kidney disease:
↑Renal dysfunction
–Uremic toxin
Kidneys
Bacteria turn carbohydrates they ferment into short-chain fatty acids by a form of fermentation called
saccharolytic fermentation.[41] Products include acetic acid, propionic acid and butyric acid.[7][41] These
materials can be used by host cells, providing a major source of energy and nutrients.[41] Gases (which are
involved in signaling[81] and may cause flatulence) and organic acids, such as lactic acid, are also produced
by fermentation.[7] Acetic acid is used by muscle, propionic acid facilitates liver production of ATP, and
butyric acid provides energy to gut cells.[41]
Gut flora also synthesize vitamins like biotin and folate, and facilitate absorption of dietary minerals,
including magnesium, calcium, and iron.[6][24] Methanobrevibacter smithii is unique because it is not a
species of bacteria, but rather a member of domain Archaea, and is the most abundant methane-producing
archaeal species in the human gastrointestinal microbiota.[82]
Gut microbiota also serve as a source of vitamins K and B12, which are not produced by the body or
produced in little amount.[83][84]
Bacteria that degrade cellulose (such as Ruminococcus) are prevalent among great apes, ancient human
societies, hunter-gatherer communities, and even modern rural populations. However, they are rare in
industrialized societies. Human-associated strains have acquired genes that can degrade specific plant fibers
such as maize, rice, and wheat. Bacterial strains found in primates can also degrade chitin, a polymer
abundant in insects, which are part of the diet of many nonhuman primates. The decline of these bacteria in
the human gut were likely influenced by the shift toward western lifestyles.[85]
The human metagenome (i.e., the genetic composition of an individual and all microorganisms that reside
on or within the individual's body) varies considerably between individuals.[86][87] Since the total number
of microbial cells in the human body (over 100 trillion) greatly outnumbers Homo sapiens cells (tens of
trillions),[note 1][86][88] there is considerable potential for interactions between drugs and an individual's
microbiome, including: drugs altering the composition of the human microbiome, drug metabolism by
microbial enzymes modifying the drug's pharmacokinetic profile, and microbial drug metabolism affecting a
drug's clinical efficacy and toxicity profile.[86][87][89]
Apart from carbohydrates, gut microbiota can also metabolize other xenobiotics such as drugs,
phytochemicals, and food toxicants. More than 30 drugs have been shown to be metabolized by gut
microbiota.[90] The microbial metabolism of drugs can sometimes inactivate the drug.[91]
The gut microbiota is an enriched community that contains diverse genes with huge biochemical capabilities
to modify drugs, especially those taken by mouth.[92] Gut microbiota can affect drug metabolism via direct
and indirect mechanisms.[93] The direct mechanism is mediated by the microbial enzymes that can modify
the chemical structure of the administered drugs.[94] Conversely, the indirect pathway is mediated by the
microbial metabolites which affect the expression of host metabolizing enzymes such as cytochrome
P450.[95][93] The effects of the gut microbiota on the pharmacokinetics and bioavailability of the drug have
been investigated a few decades ago.[96][97][98] These effects can be varied; it could activate the inactive
Cellulose degradation
Pharmacomicrobiomics
Contribution to drug metabolism
drugs such as lovastatin,[99] inactivate the active drug such as digoxin[100] or induce drug toxicity as in
irinotecan.[101] Since then, the impacts of the gut microbiota on the pharmacokinetics of many drugs were
heavily studied.[102][92]
The human gut microbiota plays a crucial role in modulating the effect of the administered drugs on the
human. Directly, gut microbiota can synthesize and release a series of enzymes with the capability to
metabolize drugs such as microbial biotransformation of L-dopa by decarboxylase and dehydroxylase
enzymes.[94] On the contrary, gut microbiota may also alter the metabolism of the drugs by modulating the
host drug metabolism. This mechanism can be mediated by microbial metabolites or by modifying host
metabolites which in turn change the expression of host metabolizing enzymes.[95]
A large number of studies have demonstrated the metabolism of over 50 drugs by the gut
microbiota.[102][93] For example, lovastatin (a cholesterol-lowering agent) which is a lactone prodrug is
partially activated by the human gut microbiota forming active acid hydroxylated metabolites.[99]
Conversely, digoxin (a drug used to treat Congestive Heart Failure) is inactivated by a member of the gut
microbiota (i.e. Eggerthella lanta).[103] Eggerthella lanta has a cytochrome-encoding operon up-regulated
by digoxin and associated with digoxin-inactivation.[103] Gut microbiota can also modulate the efficacy and
toxicity of chemotherapeutic agents such as irinotecan.[104] This effect is derived from the microbiome-
encoded β-glucuronidase enzymes which recover the active form of the irinotecan causing gastrointestinal
toxicity.[105]
This microbial community in the gut has a huge biochemical capability to produce distinct secondary
metabolites that are sometimes produced from the metabolic conversion of dietary foods such as fibers,
endogenous biological compounds such as indole or bile acids.[106][107][108] Microbial metabolites
especially short chain fatty acids (SCFAs) and secondary bile acids (BAs) play important roles for the
human in health and disease states.[109][110][111]
One of the most important bacterial metabolites produced by the gut microbiota is secondary bile acids
(BAs).[108] These metabolites are produced by the bacterial biotransformation of the primary bile acids such
as cholic acid (CA) and chenodeoxycholic acid (CDCA) into secondary bile acids (BAs) lithocholic acid
(LCA) and deoxy cholic acid (DCA) respectively.[112] Primary bile acids which are synthesized by
hepatocytes and stored in the gall bladder possess hydrophobic characters. These metabolites are
subsequently metabolized by the gut microbiota into secondary metabolites with increased
hydrophobicity.[112] Bile salt hydrolases (BSH) which are conserved across gut microbiota phyla such as
Bacteroides, Firmicutes, and Actinobacteria responsible for the first step of secondary bile acids
metabolism.[112] Secondary bile acids (BAs) such as DCA and LCA have been demonstrated to inhibit
both Clostridium difficile germination and outgrowth.[111]
The gut microbiota is important for maintaining homeostasis in the intestine. Development of intestinal
cancer is associated with an imbalance in the natural microflora (dysbiosis).[113] The secondary bile acid
deoxycholic acid is associated with alterations of the microbial community that lead to increased intestinal
carcinogenesis.[113] Increased exposure of the colon to secondary bile acids resulting from dysbiosis can
cause DNA damage, and such damage can produce carcinogenic mutations in cells of the colon.[114] The
Secondary metabolites
Dysbiosis
high density of bacteria in the colon (about 1012 per ml.) that are subject to dysbiosis compared to the
relatively low density in the small intestine (about 102 per ml.) may account for the greater than 10-fold
higher incidence of cancer in the colon compared to the small intestine.[114]
The gut–brain axis is the biochemical signaling that takes place between the gastrointestinal tract and the
central nervous system.[70] That term has been expanded to include the role of the gut flora in the interplay;
the term "microbiome––brain axis" is sometimes used to describe paradigms explicitly including the gut
flora.[70][115][116] Broadly defined, the gut–brain axis includes the central nervous system, neuroendocrine
and neuroimmune systems including the hypothalamic–pituitary–adrenal axis (HPA axis), sympathetic and
parasympathetic arms of the autonomic nervous system including the enteric nervous system, the vagus
nerve, and the gut microbiota.[70][116]
A systematic review from 2016 examined the preclinical and small human trials that have been conducted
with certain commercially available strains of probiotic bacteria and found that among those tested,
Bifidobacterium and Lactobacillus genera (B. longum, B. breve, B. infantis, L. helveticus, L. rhamnosus, L.
plantarum, and L. casei), had the most potential to be useful for certain central nervous system
disorders.[16]
Altering the numbers of gut bacteria, for example by taking broad-spectrum antibiotics, may affect the host's
health and ability to digest food.[117] Antibiotics can cause antibiotic-associated diarrhea by irritating the
bowel directly, changing the levels of microbiota, or allowing pathogenic bacteria to grow.[7] Another
harmful effect of antibiotics is the increase in numbers of antibiotic-resistant bacteria found after their use,
which, when they invade the host, cause illnesses that are difficult to treat with antibiotics.[117]
Changing the numbers and species of gut microbiota can reduce the body's ability to ferment carbohydrates
and metabolize bile acids and may cause diarrhea. Carbohydrates that are not broken down may absorb too
much water and cause runny stools, or lack of SCFAs produced by gut microbiota could cause diarrhea.[7]
A reduction in levels of native bacterial species also disrupts their ability to inhibit the growth of harmful
species such as C. difficile and Salmonella kedougou, and these species can get out of hand, though their
overgrowth may be incidental and not be the true cause of diarrhea.[6][7][117] Emerging treatment protocols
for C. difficile infections involve fecal microbiota transplantation of donor feces (see Fecal transplant).[118]
Initial reports of treatment describe success rates of 90%, with few side effects. Efficacy is speculated to
result from restoring bacterial balances of bacteroides and firmicutes classes of bacteria.[119]
The composition of the gut microbiome also changes in severe illnesses, due not only to antibiotic use but
also to such factors as ischemia of the gut, failure to eat, and immune compromise. Negative effects from
this have led to interest in selective digestive tract decontamination, a treatment to kill only pathogenic
bacteria and allow the re-establishment of healthy ones.[120]
Gut–brain axis
Alterations in microbiota balance
Effects of antibiotic use
Antibiotics alter the population of the microbiota in the gastrointestinal tract, and this may change the intra-
community metabolic interactions, modify caloric intake by using carbohydrates, and globally affects host
metabolic, hormonal and immune homeostasis.[121]
There is reasonable evidence that taking probiotics containing Lactobacillus species may help prevent
antibiotic-associated diarrhea and that taking probiotics with Saccharomyces (e.g., Saccharomyces boulardii
) may help to prevent Clostridium difficile infection following systemic antibiotic treatment.[122]
The gut microbiota of a woman changes as pregnancy advances, with the changes similar to those seen in
metabolic syndromes such as diabetes. The change in gut microbiota causes no ill effects. The newborn's
gut microbiota resemble the mother's first-trimester samples. The diversity of the microbiome decreases
from the first to third trimester, as the numbers of certain species go up.[58][123]
Probiotics are microorganisms that are believed to provide health benefits when consumed.[124][125] With
regard to gut microbiota, prebiotics are typically non-digestible, fiber compounds that pass undigested
through the upper part of the gastrointestinal tract and stimulate the growth or activity of advantageous gut
flora by acting as substrate for them.[41][126]
Synbiotics refers to food ingredients or dietary supplements combining probiotics and prebiotics in a form
of synergism.[127]
The term "pharmabiotics" is used in various ways, to mean: pharmaceutical formulations (standardized
manufacturing that can obtain regulatory approval as a drug) of probiotics, prebiotics, or synbiotics;[128]
probiotics that have been genetically engineered or otherwise optimized for best performance (shelf life,
survival in the digestive tract, etc.);[129] and the natural products of gut flora metabolism (vitamins,
etc.).[130]
There is some evidence that treatment with some probiotic strains of bacteria may be effective in irritable
bowel syndrome[131] [132] and chronic idiopathic constipation. Those organisms most likely to result in a
decrease of symptoms have included:
Bifidobacterium breve
Bifidobacterium infantis
Enterococcus faecium
Lactobacillus plantarum
Lactobacillus reuteri
Lactobacillus rhamnosus
Lactobacillus salivarius
Propionibacterium freudenreichii
Saccharomyces boulardii
Escherichia coli Nissle 1917
Pregnancy
Probiotics, prebiotics, synbiotics, and pharmabiotics
Streptococcus thermophilus[133][134][135]
Feces of about 10–15% of people consistently floats in toilet water ('floaters'), while the rest produce feces
that sinks ('sinkers') and production of gas causes feces to float.[136] While conventional mice often produce
'floaters', gnotobiotic germfree mice no gut microbiota (bred in germfree isolator) produce 'sinkers', and gut
microbiota colonization in germfree mice leads to food transformation to microbial biomass and enrichment
of multiple gasogenic bacterial species that turns the 'sinkers' into 'floaters'.[137]
Tests for whether non-antibiotic drugs may impact human gut-associated bacteria were performed by in
vitro analysis on more than 1000 marketed drugs against 40 gut bacterial strains, demonstrating that 24% of
the drugs inhibited the growth of at least one of the bacterial strains.[138]
Gut microbiota and exercise have recently been shown to be interconnected. Both moderate and intense
exercise are typically part of the training regimen of endurance athletes, but they exert different effects on
health. The interconnection between gut microbiota and endurance sports depends upon exercise intensity
and training status.[139]
Bacteria in the digestive tract can contribute to and be affected by disease in various ways. The presence or
overabundance of some kinds of bacteria may contribute to inflammatory disorders such as inflammatory
bowel disease.[6] Additionally, metabolites from certain members of the gut flora may influence host
signalling pathways, contributing to disorders such as obesity and colon cancer.[6] Some gut bacteria may
also cause infections and sepsis, for example when they are allowed to pass from the gut into the rest of the
body.[6]
Helicobacter pylori infection can initiate formation of stomach ulcers when the bacteria penetrate the
stomach epithelial lining, then causing an inflammatory phagocytotic response.[140] In turn, the
inflammation damages parietal cells which release excessive hydrochloric acid into the stomach and
produce less of the protective mucus.[141] Injury to the stomach lining, leading to ulcers, develops when
gastric acid overwhelms the defensive properties of cells and inhibits endogenous prostaglandin synthesis,
reduces mucus and bicarbonate secretion, reduces mucosal blood flow, and lowers resistance to injury.[141]
Reduced protective properties of the stomach lining increase vulnerability to further injury and ulcer
formation by stomach acid, pepsin, and bile salts.[140][141]
Fecal floatation
Research
Effects of exercise
Role in disease
Ulcers
Bowel perforation
Normally-commensal bacteria can harm the host if they extrude from the intestinal tract.[12][13]
Translocation, which occurs when bacteria leave the gut through its mucosal lining, can occur in a number
of different diseases.[13] If the gut is perforated, bacteria invade the interstitium, causing a potentially fatal
infection.[5]: 
715 
The two main types of inflammatory bowel diseases, Crohn's disease and ulcerative colitis, are chronic
inflammatory disorders of the gut; the causes of these diseases are unknown and issues with the gut flora
and its relationship with the host have been implicated in these conditions.[15][142][143][144] Additionally, it
appears that interactions of gut flora with the gut–brain axis have a role in IBD, with physiological stress
mediated through the hypothalamic–pituitary–adrenal axis driving changes to intestinal epithelium and the
gut flora in turn releasing factors and metabolites that trigger signaling in the enteric nervous system and the
vagus nerve.[4]
The diversity of gut flora appears to be significantly diminished in people with inflammatory bowel diseases
compared to healthy people; additionally, in people with ulcerative colitis, Proteobacteria and Actinobacteria
appear to dominate; in people with Crohn's, Enterococcus faecium and several Proteobacteria appear to be
over-represented.[4]
There is reasonable evidence that correcting gut flora imbalances by taking probiotics with Lactobacilli and
Bifidobacteria can reduce visceral pain and gut inflammation in IBD.[122]
Irritable bowel syndrome is a result of stress and chronic activation of the HPA axis; its symptoms include
abdominal pain, changes in bowel movements, and an increase in proinflammatory cytokines. Overall,
studies have found that the luminal and mucosal microbiota are changed in irritable bowel syndrome
individuals, and these changes can relate to the type of irritation such as diarrhea or constipation. Also, there
is a decrease in the diversity of the microbiome with low levels of fecal Lactobacilli and Bifidobacteria,
high levels of facultative anaerobic bacteria such as Escherichia coli, and increased ratios of Firmicutes:
Bacteroidetes.[116]
With asthma, two hypotheses have been posed to explain its rising prevalence in the developed world. The
hygiene hypothesis posits that children in the developed world are not exposed to enough microbes and
thus may contain lower prevalence of specific bacterial taxa that play protective roles.[145] The second
hypothesis focuses on the Western pattern diet, which lacks whole grains and fiber and has an
overabundance of simple sugars.[15] Both hypotheses converge on the role of short-chain fatty acids
(SCFAs) in immunomodulation. These bacterial fermentation metabolites are involved in immune signalling
that prevents the triggering of asthma and lower SCFA levels are associated with the disease.[145][146]
Lacking protective genera such as Lachnospira, Veillonella, Rothia and Faecalibacterium has been linked
to reduced SCFA levels.[145] Further, SCFAs are the product of bacterial fermentation of fiber, which is low
Inflammatory bowel diseases
Irritable bowel syndrome
Asthma
in the Western pattern diet.[15][146] SCFAs offer a link between gut flora and immune disorders, and as of
2016, this was an active area of research.[15] Similar hypotheses have also been posited for the rise of food
and other allergies.[147]
The connection between the gut microbiota and diabetes mellitus type 1 has also been linked to SCFAs,
such as butyrate and acetate. Diets yielding butyrate and acetate from bacterial fermentation show increased
Treg expression.[148] Treg cells downregulate effector T cells, which in turn reduces the inflammatory
response in the gut.[149] Butyrate is an energy source for colon cells. butyrate-yielding diets thus decrease
gut permeability by providing sufficient energy for the formation of tight junctions.[150] Additionally,
butyrate has also been shown to decrease insulin resistance, suggesting gut communities low in butyrate-
producing microbes may increase chances of acquiring diabetes mellitus type 2.[151] Butyrate-yielding diets
may also have potential colorectal cancer suppression effects.[150]
The gut flora have been implicated in obesity and metabolic syndrome due to a key role in the digestive
process; the Western pattern diet appears to drive and maintain changes in the gut flora that in turn change
how much energy is derived from food and how that energy is used.[144][152] One aspect of a healthy diet
that is often lacking in the Western-pattern diet is fiber and other complex carbohydrates that a healthy gut
flora require flourishing; changes to gut flora in response to a Western-pattern diet appear to increase the
amount of energy generated by the gut flora which may contribute to obesity and metabolic syndrome.[122]
There is also evidence that microbiota influence eating behaviours based on the preferences of the
microbiota, which can lead to the host consuming more food eventually resulting in obesity. It has generally
been observed that with higher gut microbiome diversity, the microbiota will spend energy and resources on
competing with other microbiota and less on manipulating the host. The opposite is seen with lower gut
microbiome diversity, and these microbiotas may work together to create host food cravings.[52]
Additionally, the liver plays a dominant role in blood glucose homeostasis by maintaining a balance
between the uptake and storage of glucose through the metabolic pathways of glycogenesis and
gluconeogenesis. Intestinal lipids regulate glucose homeostasis involving a gut–brain–liver axis. The direct
administration of lipids into the upper intestine increases the long chain fatty acyl-coenzyme A (LCFA-
CoA) levels in the upper intestines and suppresses glucose production even under subdiaphragmatic
vagotomy or gut vagal deafferentation. This interrupts the neural connection between the brain and the gut
and blocks the upper intestinal lipids' ability to inhibit glucose production. The gut–brain–liver axis and gut
microbiota composition can regulate the glucose homeostasis in the liver and provide potential therapeutic
methods to treat obesity and diabetes.[153]
Just as gut flora can function in a feedback loop that can drive the development of obesity, there is evidence
that restricting intake of calories (i.e., dieting) can drive changes to the composition of the gut flora.[144]
The composition of the human gut microbiome is similar to that of the other great apes. However, humans'
gut biota has decreased in diversity and changed in composition since our evolutionary split from Pan.[154]
Humans display increases in Bacteroidetes, a bacterial phylum associated with diets high in animal protein
Diabetes mellitus type 1
Obesity and metabolic syndrome
Other animals
and fat, and decreases in Methanobrevibacter and Fibrobacter, groups that ferment complex plant
polysaccharides.[154] These changes are the result of the combined dietary, genetic, and cultural changes
humans have undergone since evolutionary divergence from Pan.
In addition to humans and vertebrates, some insects also have complex and diverse gut microbiota that play
key nutritional roles.[2] Microbial communities associated with termites can constitute a majority of the
weight of the individuals and perform important roles in the digestion of lignocellulose and nitrogen
fixation.[155] These communities are host-specific, and closely related insect species share comparable
similarities in gut microbiota composition.[156][157] In cockroaches, gut microbiota have been shown to
assemble in a deterministic fashion, irrespective of the inoculum;[158] the reason for this host-specific
assembly remains unclear. Bacterial communities associated with insects like termites and cockroaches are
determined by a combination of forces, primarily diet, but there is some indication that host phylogeny may
also be playing a role in the selection of lineages.[156][157]
For more than 51 years it has been known that the administration of low doses of antibacterial agents
promotes the growth of farm animals to increase weight gain.[121]
In a study carried out on mice the ratio of Firmicutes and Lachnospiraceae was significantly elevated in
animals treated with subtherapeutic doses of different antibiotics. By analyzing the caloric content of faeces
and the concentration of small chain fatty acids (SCFAs) in the GI tract, it was concluded that the changes
in the composition of microbiota lead to an increased capacity to extract calories from otherwise indigestible
constituents, and to an increased production of SCFAs. These findings provide evidence that antibiotics
perturb not only the composition of the GI microbiome but also its metabolic capabilities, specifically with
respect to SCFAs.[121]
Biology portal
Medicine portal
Colonisation resistance
List of human flora
List of microbiota species of the lower reproductive tract of women
Skin flora
Verotoxin-producing Escherichia coli
1. There is substantial variation in microbiome composition and microbial concentrations by
anatomical site.[86][87] Fluid from the human colon – which contains the highest
concentration of microbes of any anatomical site – contains approximately one trillion
(10^12) bacterial cells/ml.[86]
1. Moszak, M; Szulińska, M; Bogdański, P (15 April 2020). "You Are What You Eat – The
Relationship between Diet, Microbiota, and Metabolic Disorders-A Review" (https://www.ncb
See also
Notes
References
i.nlm.nih.gov/pmc/articles/PMC7230850). Nutrients. 12 (4): 1096. doi:10.3390/nu12041096
(https://doi.org/10.3390%2Fnu12041096). PMC 7230850 (https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC7230850). PMID 32326604 (https://pubmed.ncbi.nlm.nih.gov/32326604).
S2CID 216108564 (https://api.semanticscholar.org/CorpusID:216108564).
2. Engel, P.; Moran, N. (2013). "The gut microbiota of insects–diversity in structure and
function" (https://doi.org/10.1111%2F1574-6976.12025). FEMS Microbiology Reviews. 37
(5): 699–735. doi:10.1111/1574-6976.12025 (https://doi.org/10.1111%2F1574-6976.12025).
PMID 23692388 (https://pubmed.ncbi.nlm.nih.gov/23692388).
3. Segata, N; Boernigen, D; Tickle, TL; Morgan, XC; Garrett, WS; Huttenhower, C (14 May
2013). "Computational meta'omics for microbial community studies" (https://www.ncbi.nlm.ni
h.gov/pmc/articles/PMC4039370). Molecular Systems Biology. 9: 666.
doi:10.1038/msb.2013.22 (https://doi.org/10.1038%2Fmsb.2013.22). PMC 4039370 (https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC4039370). PMID 23670539 (https://pubmed.ncbi.nl
m.nih.gov/23670539).
4. Saxena, R.; Sharma, V.K (2016). "A Metagenomic Insight Into the Human Microbiome: Its
Implications in Health and Disease" (https://books.google.com/books?id=3ylOBQAAQBAJ&
pg=PA117). In Kumar, D.; S. Antonarakis (eds.). Medical and Health Genomics. Elsevier
Science. p. 117. doi:10.1016/B978-0-12-420196-5.00009-5 (https://doi.org/10.1016%2FB97
8-0-12-420196-5.00009-5). ISBN 978-0-12-799922-7.
5. Sherwood, Linda; Willey, Joanne; Woolverton, Christopher (2013). Prescott's Microbiology (h
ttps://books.google.com/books?id=sBCSRAAACAAJ) (9th ed.). New York: McGraw Hill.
pp. 713–721. ISBN 9780073402406. OCLC 886600661 (https://www.worldcat.org/oclc/8866
00661).
6. Guarner, F; Malagelada, J (2003). "Gut flora in health and disease". The Lancet. 361 (9356):
512–519. doi:10.1016/S0140-6736(03)12489-0 (https://doi.org/10.1016%2FS0140-6736%28
03%2912489-0). PMID 12583961 (https://pubmed.ncbi.nlm.nih.gov/12583961).
S2CID 38767655 (https://api.semanticscholar.org/CorpusID:38767655).
7. Beaugerie, Laurent; Petit, Jean-Claude (2004). "Antibiotic-associated diarrhoea". Best
Practice & Research Clinical Gastroenterology. 18 (2): 337–352.
doi:10.1016/j.bpg.2003.10.002 (https://doi.org/10.1016%2Fj.bpg.2003.10.002).
PMID 15123074 (https://pubmed.ncbi.nlm.nih.gov/15123074).
8. Stephen, A. M.; Cummings, J. H. (1980). "The Microbial Contribution to Human Faecal
Mass" (https://doi.org/10.1099%2F00222615-13-1-45). Journal of Medical Microbiology. 13
(1): 45–56. doi:10.1099/00222615-13-1-45 (https://doi.org/10.1099%2F00222615-13-1-45).
PMID 7359576 (https://pubmed.ncbi.nlm.nih.gov/7359576).
9. Quigley, E. M (2013). "Gut bacteria in health and disease" (https://www.ncbi.nlm.nih.gov/pm
c/articles/PMC3983973). Gastroenterology & Hepatology. 9 (9): 560–569. PMC 3983973 (htt
ps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983973). PMID 24729765 (https://pubmed.ncb
i.nlm.nih.gov/24729765).
10. Turnbaugh, Peter J.; Ley, Ruth E.; Hamady, Micah; Fraser-Liggett, Claire M.; Knight, Rob;
Gordon, Jeffrey I. (October 2007). "The Human Microbiome Project" (https://www.ncbi.nlm.ni
h.gov/pmc/articles/PMC3709439). Nature. 449 (7164): 804–810.
Bibcode:2007Natur.449..804T (https://ui.adsabs.harvard.edu/abs/2007Natur.449..804T).
doi:10.1038/nature06244 (https://doi.org/10.1038%2Fnature06244). ISSN 0028-0836 (http
s://www.worldcat.org/issn/0028-0836). PMC 3709439 (https://www.ncbi.nlm.nih.gov/pmc/arti
cles/PMC3709439). PMID 17943116 (https://pubmed.ncbi.nlm.nih.gov/17943116).
11. Ma, Guangyu; Shi, Yuguo; Meng, Lulu; Fan, Haolong; Tang, Xiaomei; Luo, Huijuan; Wang,
Dongju; Zhou, Juan; Xiao, Xiaomin (2023). "Factors affecting the early establishment of
neonatal intestinal flora and its intervention measures" (https://www.ncbi.nlm.nih.gov/pmc/arti
cles/PMC10722192). Frontiers in Cellular and Infection Microbiology. 13.
doi:10.3389/fcimb.2023.1295111 (https://doi.org/10.3389%2Ffcimb.2023.1295111).
ISSN 2235-2988 (https://www.worldcat.org/issn/2235-2988). PMC 10722192 (https://www.nc
bi.nlm.nih.gov/pmc/articles/PMC10722192). PMID 38106467 (https://pubmed.ncbi.nlm.nih.g
ov/38106467).
12. Sommer, Felix; Bäckhed, Fredrik (2013). "The gut microbiota – masters of host development
and physiology". Nature Reviews Microbiology. 11 (4): 227–238. doi:10.1038/nrmicro2974
(https://doi.org/10.1038%2Fnrmicro2974). PMID 23435359 (https://pubmed.ncbi.nlm.nih.gov/
23435359). S2CID 22798964 (https://api.semanticscholar.org/CorpusID:22798964).
13. Faderl, Martin; Noti, Mario; Corazza, Nadia; Mueller, Christoph (2015). "Keeping bugs in
check: The mucus layer as a critical component in maintaining intestinal homeostasis" (http
s://doi.org/10.1002%2Fiub.1374). IUBMB Life. 67 (4): 275–285. doi:10.1002/iub.1374 (https://
doi.org/10.1002%2Fiub.1374). PMID 25914114 (https://pubmed.ncbi.nlm.nih.gov/25914114).
S2CID 25878594 (https://api.semanticscholar.org/CorpusID:25878594).
14. Clarke, Gerard; Stilling, Roman M; Kennedy, Paul J; Stanton, Catherine; Cryan, John F;
Dinan, Timothy G (2014). "Minireview: Gut Microbiota: The Neglected Endocrine Organ" (htt
ps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414803). Molecular Endocrinology. 28 (8):
1221–1238. doi:10.1210/me.2014-1108 (https://doi.org/10.1210%2Fme.2014-1108).
PMC 5414803 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414803). PMID 24892638 (h
ttps://pubmed.ncbi.nlm.nih.gov/24892638).
15. Shen, Sj; Wong, Connie HY (2016). "Bugging inflammation: Role of the gut microbiota" (http
s://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855262). Clinical & Translational Immunology. 5
(4): e72. doi:10.1038/cti.2016.12 (https://doi.org/10.1038%2Fcti.2016.12). PMC 4855262 (htt
ps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855262). PMID 27195115 (https://pubmed.ncb
i.nlm.nih.gov/27195115).
16. Wang, Huiying; Lee, In-Seon; Braun, Christoph; Enck, Paul (2016). "Effect of Probiotics on
Central Nervous System Functions in Animals and Humans: A Systematic Review" (https://w
ww.ncbi.nlm.nih.gov/pmc/articles/PMC5056568). Journal of Neurogastroenterology and
Motility. 22 (4): 589–605. doi:10.5056/jnm16018 (https://doi.org/10.5056%2Fjnm16018).
PMC 5056568 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056568). PMID 27413138 (h
ttps://pubmed.ncbi.nlm.nih.gov/27413138).
17. Sears, Cynthia L. (2005). "A dynamic partnership: Celebrating our gut flora". Anaerobe. 11
(5): 247–251. doi:10.1016/j.anaerobe.2005.05.001 (https://doi.org/10.1016%2Fj.anaerobe.20
05.05.001). PMID 16701579 (https://pubmed.ncbi.nlm.nih.gov/16701579).
18. Shapira, Michael (2016-07-01). "Gut Microbiotas and Host Evolution: Scaling Up Symbiosis"
(https://www.cell.com/trends/ecology-evolution/abstract/S0169-5347(16)00085-9). Trends in
Ecology & Evolution. 31 (7): 539–549. doi:10.1016/j.tree.2016.03.006 (https://doi.org/10.101
6%2Fj.tree.2016.03.006). ISSN 0169-5347 (https://www.worldcat.org/issn/0169-5347).
PMID 27039196 (https://pubmed.ncbi.nlm.nih.gov/27039196).
19. Walker, Alan W.; Hoyles, Lesley (August 2023). "Human microbiome myths and
misconceptions" (https://doi.org/10.1038%2Fs41564-023-01426-7). Nature Microbiology. 8
(8): 1392–1396. doi:10.1038/s41564-023-01426-7 (https://doi.org/10.1038%2Fs41564-023-0
1426-7). ISSN 2058-5276 (https://www.worldcat.org/issn/2058-5276). PMID 37524974 (http
s://pubmed.ncbi.nlm.nih.gov/37524974).
20. Lozupone, Catherine A.; Stombaugh, Jesse I.; Gordon, Jeffrey I.; Jansson, Janet K.; Knight,
Rob (2012). "Diversity, stability and resilience of the human gut microbiota" (https://www.ncb
i.nlm.nih.gov/pmc/articles/PMC3577372). Nature. 489 (7415): 220–230.
Bibcode:2012Natur.489..220L (https://ui.adsabs.harvard.edu/abs/2012Natur.489..220L).
doi:10.1038/nature11550 (https://doi.org/10.1038%2Fnature11550). PMC 3577372 (https://w
ww.ncbi.nlm.nih.gov/pmc/articles/PMC3577372). PMID 22972295 (https://pubmed.ncbi.nlm.
nih.gov/22972295).
21. Qin, Junjie; Li, Ruiqiang; Raes, Jeroen; Arumugam, Manimozhiyan; Burgdorf, Kristoffer
Solvsten; Manichanh, Chaysavanh; Nielsen, Trine; Pons, Nicolas; Levenez, Florence;
Yamada, Takuji; Mende, Daniel R.; Li, Junhua; Xu, Junming; Li, Shaochuan; Li, Dongfang;
Cao, Jianjun; Wang, Bo; Liang, Huiqing; Zheng, Huisong; Xie, Yinlong; Tap, Julien; Lepage,
Patricia; Bertalan, Marcelo; Batto, Jean-Michel; Hansen, Torben; Le Paslier, Denis;
Linneberg, Allan; Nielsen, H. Bjørn; Pelletier, Eric; Renault, Pierre (2010). "A human gut
microbial gene catalogue established by metagenomic sequencing" (https://www.ncbi.nlm.ni
h.gov/pmc/articles/PMC3779803). Nature. 464 (7285): 59–65. Bibcode:2010Natur.464...59.
(https://ui.adsabs.harvard.edu/abs/2010Natur.464...59.). doi:10.1038/nature08821 (https://do
i.org/10.1038%2Fnature08821). PMC 3779803 (https://www.ncbi.nlm.nih.gov/pmc/articles/P
MC3779803). PMID 20203603 (https://pubmed.ncbi.nlm.nih.gov/20203603).
22. Shanahan, Fergus (2002). "The host–microbe interface within the gut". Best Practice &
Research Clinical Gastroenterology. 16 (6): 915–931. doi:10.1053/bega.2002.0342 (https://d
oi.org/10.1053%2Fbega.2002.0342). PMID 12473298 (https://pubmed.ncbi.nlm.nih.gov/1247
3298).
23. Tap, Julien; Mondot, Stanislas; Levenez, Florence; Pelletier, Eric; Caron, Christophe; Furet,
Jean-Pierre; Ugarte, Edgardo; Muñoz-Tamayo, Rafael; Paslier, Denis L. E.; Nalin, Renaud;
Dore, Joel; Leclerc, Marion (2009). "Towards the human intestinal microbiota phylogenetic
core" (https://doi.org/10.1111%2Fj.1462-2920.2009.01982.x). Environmental Microbiology.
11 (10): 2574–2584. Bibcode:2009EnvMi..11.2574T (https://ui.adsabs.harvard.edu/abs/2009
EnvMi..11.2574T). doi:10.1111/j.1462-2920.2009.01982.x (https://doi.org/10.1111%2Fj.1462
-2920.2009.01982.x). PMID 19601958 (https://pubmed.ncbi.nlm.nih.gov/19601958).
24. O'Hara, Ann M; Shanahan, Fergus (2006). "The gut flora as a forgotten organ" (https://www.n
cbi.nlm.nih.gov/pmc/articles/PMC1500832). EMBO Reports. 7 (7): 688–693.
doi:10.1038/sj.embor.7400731 (https://doi.org/10.1038%2Fsj.embor.7400731).
PMC 1500832 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1500832). PMID 16819463 (h
ttps://pubmed.ncbi.nlm.nih.gov/16819463).
25. Khanna, Sahil; Tosh, Pritish K (2014). "A Clinician's Primer on the Role of the Microbiome in
Human Health and Disease". Mayo Clinic Proceedings. 89 (1): 107–114.
doi:10.1016/j.mayocp.2013.10.011 (https://doi.org/10.1016%2Fj.mayocp.2013.10.011).
PMID 24388028 (https://pubmed.ncbi.nlm.nih.gov/24388028).
26. Cui, Lijia; Morris, Alison; Ghedin, Elodie (2013). "The human mycobiome in health and
disease" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978422). Genome Medicine. 5 (7):
63. doi:10.1186/gm467 (https://doi.org/10.1186%2Fgm467). PMC 3978422 (https://www.ncb
i.nlm.nih.gov/pmc/articles/PMC3978422). PMID 23899327 (https://pubmed.ncbi.nlm.nih.gov/
23899327).
27. Erdogan, Askin; Rao, Satish S. C (2015). "Small Intestinal Fungal Overgrowth". Current
Gastroenterology Reports. 17 (4): 16. doi:10.1007/s11894-015-0436-2 (https://doi.org/10.100
7%2Fs11894-015-0436-2). PMID 25786900 (https://pubmed.ncbi.nlm.nih.gov/25786900).
S2CID 3098136 (https://api.semanticscholar.org/CorpusID:3098136).
28. Bello, Maria G. Dominguez; Knight, Rob; Gilbert, Jack A.; Blaser, Martin J. (4 October 2018).
"Preserving microbial diversity". Science. 362 (6410): 33–34. Bibcode:2018Sci...362...33B (h
ttps://ui.adsabs.harvard.edu/abs/2018Sci...362...33B). doi:10.1126/science.aau8816 (https://
doi.org/10.1126%2Fscience.aau8816). PMID 30287652 (https://pubmed.ncbi.nlm.nih.gov/30
287652). S2CID 52919917 (https://api.semanticscholar.org/CorpusID:52919917).
29. Arumugam, Manimozhiyan; Raes, Jeroen; Pelletier, Eric; Le Paslier, Denis; Yamada, Takuji;
Mende, Daniel R.; Fernandes, Gabriel R.; Tap, Julien; Bruls, Thomas; Batto, Jean-Michel;
Bertalan, Marcelo; Borruel, Natalia; Casellas, Francesc; Fernandez, Leyden; Gautier,
Laurent; Hansen, Torben; Hattori, Masahira; Hayashi, Tetsuya; Kleerebezem, Michiel;
Kurokawa, Ken; Leclerc, Marion; Levenez, Florence; Manichanh, Chaysavanh; Nielsen, H.
Bjørn; Nielsen, Trine; Pons, Nicolas; Poulain, Julie; Qin, Junjie; Sicheritz-Ponten, Thomas;
Tims, Sebastian (2011). "Enterotypes of the human gut microbiome" (https://www.ncbi.nlm.ni
h.gov/pmc/articles/PMC3728647). Nature. 473 (7346): 174–180.
Bibcode:2011Natur.473..174. (https://ui.adsabs.harvard.edu/abs/2011Natur.473..174.).
doi:10.1038/nature09944 (https://doi.org/10.1038%2Fnature09944). PMC 3728647 (https://w
ww.ncbi.nlm.nih.gov/pmc/articles/PMC3728647). PMID 21508958 (https://pubmed.ncbi.nlm.
nih.gov/21508958).
30. Wu, G. D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y.-Y.; Keilbaugh, S. A.; Bewtra, M.;
Knights, D.; Walters, W. A.; Knight, R.; Sinha, R.; Gilroy, E.; Gupta, K.; Baldassano, R.;
Nessel, L.; Li, H.; Bushman, F. D.; Lewis, J. D. (2011). "Linking Long-Term Dietary Patterns
with Gut Microbial Enterotypes" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368382).
Science. 334 (6052): 105–108. Bibcode:2011Sci...334..105W (https://ui.adsabs.harvard.edu/
abs/2011Sci...334..105W). doi:10.1126/science.1208344 (https://doi.org/10.1126%2Fscienc
e.1208344). PMC 3368382 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368382).
PMID 21885731 (https://pubmed.ncbi.nlm.nih.gov/21885731).
31. Zimmer, Carl (April 20, 2011). "Bacteria Divide People Into 3 Types, Scientists Say" (https://
www.nytimes.com/2011/04/21/science/21gut.html). The New York Times. Retrieved April 21,
2011. "a group of scientists now report just three distinct ecosystems in the guts of people
they have studied."
32. Knights, Dan; Ward, Tonya; McKinlay, Christopher; Miller, Hannah; Gonzalez, Antonio;
McDonald, Daniel; Knight, Rob (8 October 2014). "Rethinking "Enterotypes" " (https://www.n
cbi.nlm.nih.gov/pmc/articles/PMC5558460). Cell Host & Microbe. 16 (4): 433–437.
doi:10.1016/j.chom.2014.09.013 (https://doi.org/10.1016%2Fj.chom.2014.09.013).
PMC 5558460 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558460). PMID 25299329 (h
ttps://pubmed.ncbi.nlm.nih.gov/25299329).
33. Nardone, G; Compare, D (June 2015). "The human gastric microbiota: Is it time to rethink the
pathogenesis of stomach diseases?" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC448053
5). United European Gastroenterology Journal. 3 (3): 255–60.
doi:10.1177/2050640614566846 (https://doi.org/10.1177%2F2050640614566846).
PMC 4480535 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480535). PMID 26137299 (h
ttps://pubmed.ncbi.nlm.nih.gov/26137299).
34. Yao, X; Smolka, AJ (June 2019). "Gastric Parietal Cell Physiology and Helicobacter pylori-
Induced Disease" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715393).
Gastroenterology. 156 (8): 2158–2173. doi:10.1053/j.gastro.2019.02.036 (https://doi.org/10.1
053%2Fj.gastro.2019.02.036). PMC 6715393 (https://www.ncbi.nlm.nih.gov/pmc/articles/PM
C6715393). PMID 30831083 (https://pubmed.ncbi.nlm.nih.gov/30831083).
35. Todar, Kenneth (2012). "The Normal Bacterial Flora of Humans" (http://www.textbookofbacter
iology.net/normalflora_3.html). Todar's Online Textbook of Bacteriology. Retrieved June 25,
2016.
36. Quigley, Eamonn M.M; Quera, Rodrigo (2006). "Small Intestinal Bacterial Overgrowth: Roles
of Antibiotics, Prebiotics, and Probiotics" (https://doi.org/10.1053%2Fj.gastro.2005.11.046).
Gastroenterology. 130 (2): S78–90. doi:10.1053/j.gastro.2005.11.046 (https://doi.org/10.105
3%2Fj.gastro.2005.11.046). PMID 16473077 (https://pubmed.ncbi.nlm.nih.gov/16473077).
S2CID 16904501 (https://api.semanticscholar.org/CorpusID:16904501).
37. Adams, M. R.; Moss, M. O. (2007). Food Microbiology. doi:10.1039/9781847557940 (https://d
oi.org/10.1039%2F9781847557940). ISBN 978-0-85404-284-5. S2CID 241261974 (https://a
pi.semanticscholar.org/CorpusID:241261974).
38. "The normal gut flora" (https://web.archive.org/web/20040526195616/http://www.gla.ac.uk/de
partments/humannutrition/students/resources/meden/Infection.pdf) (PDF) (slideshow). 2004.
Archived from the original (http://www.gla.ac.uk/departments/humannutrition/students/resour
ces/meden/Infection.pdf) (PDF) on 2004-05-26. Retrieved 2023-01-02 – via University of
Glasgow.
39. Braune A, Blaut M (2016). "Bacterial species involved in the conversion of dietary flavonoids
in the human gut" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939924). Gut Microbes. 7
(3): 216–234. doi:10.1080/19490976.2016.1158395 (https://doi.org/10.1080%2F19490976.2
016.1158395). PMC 4939924 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939924).
PMID 26963713 (https://pubmed.ncbi.nlm.nih.gov/26963713).
40. Steinhoff, U (2005). "Who controls the crowd? New findings and old questions about the
intestinal microflora". Immunology Letters. 99 (1): 12–16. doi:10.1016/j.imlet.2004.12.013 (htt
ps://doi.org/10.1016%2Fj.imlet.2004.12.013). PMID 15894105 (https://pubmed.ncbi.nlm.nih.g
ov/15894105).
41. Gibson, Glenn R (2004). "Fibre and effects on probiotics (the prebiotic concept)". Clinical
Nutrition Supplements. 1 (2): 25–31. doi:10.1016/j.clnu.2004.09.005 (https://doi.org/10.101
6%2Fj.clnu.2004.09.005).
42. Miquel, S; Martín, R; Rossi, O; Bermúdez-Humarán, LG; Chatel, JM; Sokol, H; Thomas, M;
Wells, JM; Langella, P (2013). "Faecalibacterium prausnitzii and human intestinal health".
Current Opinion in Microbiology. 16 (3): 255–261. doi:10.1016/j.mib.2013.06.003 (https://doi.
org/10.1016%2Fj.mib.2013.06.003). PMID 23831042 (https://pubmed.ncbi.nlm.nih.gov/2383
1042).
43. Ley, Ruth E (2010). "Obesity and the human microbiome". Current Opinion in
Gastroenterology. 26 (1): 5–11. doi:10.1097/MOG.0b013e328333d751 (https://doi.org/10.109
7%2FMOG.0b013e328333d751). PMID 19901833 (https://pubmed.ncbi.nlm.nih.gov/199018
33). S2CID 23329156 (https://api.semanticscholar.org/CorpusID:23329156).
44. Nash, Andrea K; Auchtung, Thomas A; Wong, Matthew C; Smith, Daniel P; Gesell, Jonathan
R; Ross, Matthew C; Stewart, Christopher J; Metcalf, Ginger A; Muzny, Donna M; Gibbs,
Richard A; Ajami, Nadim J; Petrosino, Joseph F (2017). "The gut mycobiome of the Human
Microbiome Project healthy cohort" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC570218
6). Microbiome. 5 (1): 153. doi:10.1186/s40168-017-0373-4 (https://doi.org/10.1186%2Fs401
68-017-0373-4). PMC 5702186 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702186).
PMID 29178920 (https://pubmed.ncbi.nlm.nih.gov/29178920).
45. Scarpellini, Emidio; Ianiro, Gianluca; Attili, Fabia; Bassanelli, Chiara; De Santis, Adriano;
Gasbarrini, Antonio (2015). "The human gut microbiota and virome: Potential therapeutic
implications" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185617). Digestive and Liver
Disease. 47 (12): 1007–1012. doi:10.1016/j.dld.2015.07.008 (https://doi.org/10.1016%2Fj.dl
d.2015.07.008). PMC 7185617 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185617).
PMID 26257129 (https://pubmed.ncbi.nlm.nih.gov/26257129).
46. Gerritsen, Jacoline; Smidt, Hauke; Rijkers, Ger; de Vos, Willem (27 May 2011). "Intestinal
microbiota in human health and disease: the impact of probiotics" (https://www.ncbi.nlm.nih.g
ov/pmc/articles/PMC3145058). Genes & Nutrition. 6 (3): 209–240. doi:10.1007/s12263-011-
0229-7 (https://doi.org/10.1007%2Fs12263-011-0229-7). PMC 3145058 (https://www.ncbi.nl
m.nih.gov/pmc/articles/PMC3145058). PMID 21617937 (https://pubmed.ncbi.nlm.nih.gov/21
617937).
47. Yatsunenko, T.; Rey, F. E.; Manary, M. J.; Trehan, I.; Dominguez-Bello, M. G.; Contreras, M.;
Magris, M.; Hidalgo, G.; Baldassano, R. N.; Anokhin, A. P.; Heath, A. C.; Warner, B.; Reeder,
J.; Kuczynski, J.; Caporaso, J. G.; Lozupone, C. A.; Lauber, C.; Clemente, J. C.; Knights, D.;
Knight, R.; Gordon, J. I. (2012). "Human gut microbiome viewed across age and geography"
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376388). Nature. 486 (7402): 222–227.
Bibcode:2012Natur.486..222Y (https://ui.adsabs.harvard.edu/abs/2012Natur.486..222Y).
doi:10.1038/nature11053 (https://doi.org/10.1038%2Fnature11053). PMC 3376388 (https://w
ww.ncbi.nlm.nih.gov/pmc/articles/PMC3376388). PMID 22699611 (https://pubmed.ncbi.nlm.
nih.gov/22699611).
48. De Filippo, C; Cavalieri, D; Di Paola, M; Ramazzotti, M; Poullet, J. B; Massart, S; Collini, S;
Pieraccini, G; Lionetti, P (2010). "Impact of diet in shaping gut microbiota revealed by a
comparative study in children from Europe and rural Africa" (https://www.ncbi.nlm.nih.gov/pm
c/articles/PMC2930426). Proceedings of the National Academy of Sciences. 107 (33):
14691–14696. Bibcode:2010PNAS..10714691D (https://ui.adsabs.harvard.edu/abs/2010PN
AS..10714691D). doi:10.1073/pnas.1005963107 (https://doi.org/10.1073%2Fpnas.1005963
107). PMC 2930426 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930426).
PMID 20679230 (https://pubmed.ncbi.nlm.nih.gov/20679230).
49. Jonkers, Daisy M.A.E. (2016). "Microbial perturbations and modulation in conditions
associated with malnutrition and malabsorption". Best Practice & Research Clinical
Gastroenterology. 30 (2): 161–172. doi:10.1016/j.bpg.2016.02.006 (https://doi.org/10.1016%
2Fj.bpg.2016.02.006). PMID 27086883 (https://pubmed.ncbi.nlm.nih.gov/27086883).
50. Million, Matthieu; Diallo, Aldiouma; Raoult, Didier (May 2017). "Gut microbiota and
malnutrition" (https://hal.archives-ouvertes.fr/hal-01573801/file/Million2017.pdf) (PDF).
Microbial Pathogenesis. 106: 127–138. doi:10.1016/j.micpath.2016.02.003 (https://doi.org/1
0.1016%2Fj.micpath.2016.02.003). PMID 26853753 (https://pubmed.ncbi.nlm.nih.gov/26853
753). S2CID 20381329 (https://api.semanticscholar.org/CorpusID:20381329).
51. Rytter, Maren Johanne Heilskov; Kolte, Lilian; Briend, André; Friis, Henrik; Christensen,
Vibeke Brix (2014). "The Immune System in Children with Malnutrition – A Systematic
Review" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143239). PLOS ONE. 9 (8):
e105017. Bibcode:2014PLoSO...9j5017R (https://ui.adsabs.harvard.edu/abs/2014PLoSO...9
j5017R). doi:10.1371/journal.pone.0105017 (https://doi.org/10.1371%2Fjournal.pone.01050
17). PMC 4143239 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143239).
PMID 25153531 (https://pubmed.ncbi.nlm.nih.gov/25153531).
52. Alcock, Joe; Maley, Carlo C; Aktipis, C. Athena (2014). "Is eating behavior manipulated by
the gastrointestinal microbiota? Evolutionary pressures and potential mechanisms" (https://w
ww.ncbi.nlm.nih.gov/pmc/articles/PMC4270213). BioEssays. 36 (10): 940–949.
doi:10.1002/bies.201400071 (https://doi.org/10.1002%2Fbies.201400071). PMC 4270213 (h
ttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270213). PMID 25103109 (https://pubmed.nc
bi.nlm.nih.gov/25103109).
53. Renson, Audrey; Herd, Pamela; Dowd, Jennifer B. (2020). "Sick Individuals and Sick
(Microbial) Populations: Challenges in Epidemiology and the Microbiome" (https://www.ncbi.
nlm.nih.gov/pmc/articles/PMC9713946). Annual Review of Public Health. 41: 63–80.
doi:10.1146/annurev-publhealth-040119-094423 (https://doi.org/10.1146%2Fannurev-publh
ealth-040119-094423). PMC 9713946 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC97139
46). PMID 31635533 (https://pubmed.ncbi.nlm.nih.gov/31635533).
54. Turroni, Francesca; Peano, Clelia; Pass, Daniel A; Foroni, Elena; Severgnini, Marco;
Claesson, Marcus J; Kerr, Colm; Hourihane, Jonathan; Murray, Deirdre; Fuligni, Fabio;
Gueimonde, Miguel; Margolles, Abelardo; De Bellis, Gianluca; o'Toole, Paul W; Van
Sinderen, Douwe; Marchesi, Julian R; Ventura, Marco (2012). "Diversity of Bifidobacteria
within the Infant Gut Microbiota" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350489).
PLOS ONE. 7 (5): e36957. Bibcode:2012PLoSO...736957T (https://ui.adsabs.harvard.edu/a
bs/2012PLoSO...736957T). doi:10.1371/journal.pone.0036957 (https://doi.org/10.1371%2Fj
ournal.pone.0036957). PMC 3350489 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC33504
89). PMID 22606315 (https://pubmed.ncbi.nlm.nih.gov/22606315).
55. Davenport, Emily R.; Sanders, Jon G.; Song, Se Jin; Amato, Katherine R.; Clark, Andrew G.;
Knight, Rob (2017-12-27). "The human microbiome in evolution" (https://www.ncbi.nlm.nih.g
ov/pmc/articles/PMC5744394). BMC Biology. 15 (1): 127. doi:10.1186/s12915-017-0454-7
(https://doi.org/10.1186%2Fs12915-017-0454-7). ISSN 1741-7007 (https://www.worldcat.org/
issn/1741-7007). PMC 5744394 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744394).
PMID 29282061 (https://pubmed.ncbi.nlm.nih.gov/29282061).
56. Perez-Muñoz, Maria Elisa; Arrieta, Marie-Claire; Ramer-Tait, Amanda E; Walter, Jens (2017).
"A critical assessment of the 'sterile womb' and 'in utero colonization' hypotheses:
Implications for research on the pioneer infant microbiome" (https://www.ncbi.nlm.nih.gov/pm
c/articles/PMC5410102). Microbiome. 5 (1): 48. doi:10.1186/s40168-017-0268-4 (https://doi.
org/10.1186%2Fs40168-017-0268-4). PMC 5410102 (https://www.ncbi.nlm.nih.gov/pmc/artic
les/PMC5410102). PMID 28454555 (https://pubmed.ncbi.nlm.nih.gov/28454555).
57. Matamoros, Sebastien; Gras-Leguen, Christele; Le Vacon, Françoise; Potel, Gilles; de la
Cochetiere, Marie-France (2013). "Development of intestinal microbiota in infants and its
impact on health". Trends in Microbiology. 21 (4): 167–173. doi:10.1016/j.tim.2012.12.001 (ht
tps://doi.org/10.1016%2Fj.tim.2012.12.001). PMID 23332725 (https://pubmed.ncbi.nlm.nih.go
v/23332725).
58. Mueller, Noel T.; Bakacs, Elizabeth; Combellick, Joan; Grigoryan, Zoya; Dominguez-Bello,
Maria G. (2015). "The infant microbiome development: mom matters" (https://www.ncbi.nlm.n
ih.gov/pmc/articles/PMC4464665). Trends in Molecular Medicine. 21 (2): 109–117.
doi:10.1016/j.molmed.2014.12.002 (https://doi.org/10.1016%2Fj.molmed.2014.12.002).
PMC 4464665 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464665). PMID 25578246 (h
ttps://pubmed.ncbi.nlm.nih.gov/25578246).
59. Jiménez, Esther; Fernández, Leonides; Marín, María L; Martín, Rocío; Odriozola, Juan M;
Nueno-Palop, Carmen; Narbad, Arjan; Olivares, Mónica; Xaus, Jordi; Rodríguez, Juan M
(2005). "Isolation of Commensal Bacteria from Umbilical Cord Blood of Healthy Neonates
Born by Cesarean Section". Current Microbiology. 51 (4): 270–274. doi:10.1007/s00284-
005-0020-3 (https://doi.org/10.1007%2Fs00284-005-0020-3). PMID 16187156 (https://pubm
ed.ncbi.nlm.nih.gov/16187156). S2CID 43438656 (https://api.semanticscholar.org/CorpusID:
43438656).
60. Collado, Maria Carmen; Rautava, Samuli; Aakko, Juhani; Isolauri, Erika; Salminen, Seppo
(2016). "Human gut colonisation may be initiated in utero by distinct microbial communities
in the placenta and amniotic fluid" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802384).
Scientific Reports. 6: 23129. Bibcode:2016NatSR...623129C (https://ui.adsabs.harvard.edu/
abs/2016NatSR...623129C). doi:10.1038/srep23129 (https://doi.org/10.1038%2Fsrep23129).
PMC 4802384 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802384). PMID 27001291 (h
ttps://pubmed.ncbi.nlm.nih.gov/27001291).
61. Jiménez, Esther; Marín, María L.; Martín, Rocío; Odriozola, Juan M.; Olivares, Mónica; Xaus,
Jordi; Fernández, Leonides; Rodríguez, Juan M. (2008). "Is meconium from healthy
newborns actually sterile?" (https://doi.org/10.1016%2Fj.resmic.2007.12.007). Research in
Microbiology. 159 (3): 187–193. doi:10.1016/j.resmic.2007.12.007 (https://doi.org/10.1016%2
Fj.resmic.2007.12.007). PMID 18281199 (https://pubmed.ncbi.nlm.nih.gov/18281199).
62. Perez-Muñoz, Maria Elisa; Arrieta, Marie-Claire; Ramer-Tait, Amanda E; Walter, Jens (2017).
"A critical assessment of the "sterile womb" and "in utero colonization" hypotheses:
Implications for research on the pioneer infant microbiome" (https://www.ncbi.nlm.nih.gov/pm
c/articles/PMC5410102). Microbiome. 5 (1): 48. doi:10.1186/s40168-017-0268-4 (https://doi.
org/10.1186%2Fs40168-017-0268-4). PMC 5410102 (https://www.ncbi.nlm.nih.gov/pmc/artic
les/PMC5410102). PMID 28454555 (https://pubmed.ncbi.nlm.nih.gov/28454555).
63. Adlerberth, I; Wold, AE (2009). "Establishment of the gut microbiota in Western infants". Acta
Paediatrica. 98 (2): 229–238. doi:10.1111/j.1651-2227.2008.01060.x (https://doi.org/10.111
1%2Fj.1651-2227.2008.01060.x). PMID 19143664 (https://pubmed.ncbi.nlm.nih.gov/191436
64). S2CID 205859933 (https://api.semanticscholar.org/CorpusID:205859933).
64. "Babies' gut bacteria affected by delivery method: Vaginal delivery promotes mother's gut
bacteria in babies' gut" (https://www.sciencedaily.com/releases/2019/09/190918131447.ht
m). ScienceDaily. 18 September 2019. Archived (https://web.archive.org/web/202111242051
02/www.sciencedaily.com/releases/2019/09/190918131447.htm) from the original on 24
November 2021. Retrieved 31 May 2022.
65. Coppa, G. V.; Zampini, L.; Galeazzi, T.; Gabrielli, O. (2006). "Prebiotics in human milk: A
review". Digestive and Liver Disease. 38: S291–294. doi:10.1016/S1590-8658(07)60013-9
(https://doi.org/10.1016%2FS1590-8658%2807%2960013-9). PMID 17259094 (https://pubm
ed.ncbi.nlm.nih.gov/17259094).
66. Mady, Eman A.; Doghish, Ahmed S.; El-Dakroury, Walaa A.; Elkhawaga, Samy Y.; Ismail,
Ahmed; El-Mahdy, Hesham A.; Elsakka, Elsayed G. E.; El-Husseiny, Hussein M. (2023-07-
01). "Impact of the mother's gut microbiota on infant microbiome and brain development".
Neuroscience & Biobehavioral Reviews. 150: 105195. doi:10.1016/j.neubiorev.2023.105195
(https://doi.org/10.1016%2Fj.neubiorev.2023.105195). ISSN 0149-7634 (https://www.worldca
t.org/issn/0149-7634). PMID 37100161 (https://pubmed.ncbi.nlm.nih.gov/37100161).
S2CID 258302702 (https://api.semanticscholar.org/CorpusID:258302702).
67. Fanaro, S; Chierici, R; Guerrini, P; Vigi, V (2007). "Intestinal microflora in early infancy:
Composition and development". Acta Paediatrica. 92 (441): 48–55. doi:10.1111/j.1651-
2227.2003.tb00646.x (https://doi.org/10.1111%2Fj.1651-2227.2003.tb00646.x).
PMID 14599042 (https://pubmed.ncbi.nlm.nih.gov/14599042). S2CID 10316311 (https://api.s
emanticscholar.org/CorpusID:10316311).
68. Yassour, Moran; Vatanen, Tommi; Siljander, Heli; Hämäläinen, Anu-Maaria; Härkönen,
Taina; Ryhänen, Samppa J; Franzosa, Eric A; Vlamakis, Hera; Huttenhower, Curtis; Gevers,
Dirk; Lander, Eric S; Knip, Mikael; Xavier, Ramnik J (2016). "Natural history of the infant gut
microbiome and impact of antibiotic treatment on bacterial strain diversity and stability" (http
s://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032909). Science Translational Medicine. 8
(343): 343ra81. doi:10.1126/scitranslmed.aad0917 (https://doi.org/10.1126%2Fscitranslmed.
aad0917). PMC 5032909 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032909).
PMID 27306663 (https://pubmed.ncbi.nlm.nih.gov/27306663).
69. Gibson, G. R.; Roberfroid, M. B. (1995). "Dietary modulation of the human colonic microbiota:
Introducing the concept of prebiotics" (https://pubmed.ncbi.nlm.nih.gov/7782892/). The
Journal of Nutrition. 125 (6): 1401–1412. doi:10.1093/jn/125.6.1401 (https://doi.org/10.109
3%2Fjn%2F125.6.1401). PMID 7782892 (https://pubmed.ncbi.nlm.nih.gov/7782892).
70. Wang, Yan; Kasper, Lloyd H (2014). "The role of microbiome in central nervous system
disorders" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062078). Brain, Behavior, and
Immunity. 38: 1–12. doi:10.1016/j.bbi.2013.12.015 (https://doi.org/10.1016%2Fj.bbi.2013.12.
015). PMC 4062078 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062078).
PMID 24370461 (https://pubmed.ncbi.nlm.nih.gov/24370461).
71. Yoon, My Young; Lee, Keehoon; Yoon, Sang Sun (2014). "Protective role of gut commensal
microbes against intestinal infections". Journal of Microbiology. 52 (12): 983–989.
doi:10.1007/s12275-014-4655-2 (https://doi.org/10.1007%2Fs12275-014-4655-2).
PMID 25467115 (https://pubmed.ncbi.nlm.nih.gov/25467115). S2CID 54622675 (https://api.s
emanticscholar.org/CorpusID:54622675).
72. Reinoso Webb, Cynthia; Koboziev, Iurii; Furr, Kathryn L; Grisham, Matthew B (2016).
"Protective and pro-inflammatory roles of intestinal bacteria" (https://www.ncbi.nlm.nih.gov/p
mc/articles/PMC4867289). Pathophysiology. 23 (2): 67–80.
doi:10.1016/j.pathophys.2016.02.002 (https://doi.org/10.1016%2Fj.pathophys.2016.02.002).
PMC 4867289 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867289). PMID 26947707 (h
ttps://pubmed.ncbi.nlm.nih.gov/26947707).
73. Mantis, N J; Rol, N; Corthésy, B (2011). "Secretory IgA's complex roles in immunity and
mucosal homeostasis in the gut" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774538).
Mucosal Immunology. 4 (6): 603–611. doi:10.1038/mi.2011.41 (https://doi.org/10.1038%2Fm
i.2011.41). PMC 3774538 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774538).
PMID 21975936 (https://pubmed.ncbi.nlm.nih.gov/21975936).
74. Peterson, Lance W; Artis, David (2014). "Intestinal epithelial cells: Regulators of barrier
function and immune homeostasis". Nature Reviews Immunology. 14 (3): 141–153.
doi:10.1038/nri3608 (https://doi.org/10.1038%2Fnri3608). PMID 24566914 (https://pubmed.n
cbi.nlm.nih.gov/24566914). S2CID 3351351 (https://api.semanticscholar.org/CorpusID:3351
351).
75. Honda, Kenya; Littman, Dan R (2016). "The microbiota in adaptive immune homeostasis
and disease". Nature. 535 (7610): 75–84. Bibcode:2016Natur.535...75H (https://ui.adsabs.ha
rvard.edu/abs/2016Natur.535...75H). doi:10.1038/nature18848 (https://doi.org/10.1038%2Fn
ature18848). PMID 27383982 (https://pubmed.ncbi.nlm.nih.gov/27383982). S2CID 4461492
(https://api.semanticscholar.org/CorpusID:4461492).
76. Levy, M.; Thaiss, C.A.; Elinav, E. (2016). "Metabolites: messengers between the microbiota
and the immune system" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973288). Genes &
Development. 30 (14): 1589–1597. doi:10.1101/gad.284091.116 (https://doi.org/10.1101%2F
gad.284091.116). PMC 4973288 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973288).
PMID 27474437 (https://pubmed.ncbi.nlm.nih.gov/27474437).
77. Zhang LS, Davies SS (April 2016). "Microbial metabolism of dietary components to bioactive
metabolites: opportunities for new therapeutic interventions" (https://www.ncbi.nlm.nih.gov/p
mc/articles/PMC4840492). Genome Med. 8 (1): 46. doi:10.1186/s13073-016-0296-x (https://d
oi.org/10.1186%2Fs13073-016-0296-x). PMC 4840492 (https://www.ncbi.nlm.nih.gov/pmc/ar
ticles/PMC4840492). PMID 27102537 (https://pubmed.ncbi.nlm.nih.gov/27102537).
"Lactobacillus spp. convert tryptophan to indole-3-aldehyde (I3A) through unidentified
enzymes [125]. Clostridium sporogenes convert tryptophan to IPA [6], likely via a tryptophan
deaminase. ... IPA also potently scavenges hydroxyl radicals"
Table 2: Microbial metabolites: their synthesis, mechanisms of action, and effects on health
and disease (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840492/table/Tab2/)
Figure 1: Molecular mechanisms of action of indole and its metabolites on host physiology
and disease (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840492/figure/Fig1/)
78. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G (March 2009).
"Metabolomics analysis reveals large effects of gut microflora on mammalian blood
metabolites" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656143). Proc. Natl. Acad. Sci.
U.S.A. 106 (10): 3698–3703. Bibcode:2009PNAS..106.3698W (https://ui.adsabs.harvard.ed
u/abs/2009PNAS..106.3698W). doi:10.1073/pnas.0812874106 (https://doi.org/10.1073%2Fp
nas.0812874106). PMC 2656143 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656143).
PMID 19234110 (https://pubmed.ncbi.nlm.nih.gov/19234110). "Production of IPA was shown
to be completely dependent on the presence of gut microflora and could be established by
colonization with the bacterium Clostridium sporogenes."
IPA metabolism diagram (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656143/figure/F2/)
79. "3-Indolepropionic acid" (http://www.hmdb.ca/metabolites/HMDB02302). Human
Metabolome Database. University of Alberta. Retrieved 12 June 2018.
80. Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J, Pappolla MA (July
1999). "Potent neuroprotective properties against the Alzheimer beta-amyloid by an
endogenous melatonin-related indole structure, indole-3-propionic acid" (https://doi.org/10.1
074%2Fjbc.274.31.21937). J. Biol. Chem. 274 (31): 21937–21942.
doi:10.1074/jbc.274.31.21937 (https://doi.org/10.1074%2Fjbc.274.31.21937).
PMID 10419516 (https://pubmed.ncbi.nlm.nih.gov/10419516). S2CID 6630247 (https://api.se
manticscholar.org/CorpusID:6630247). "[Indole-3-propionic acid (IPA)] has previously been
identified in the plasma and cerebrospinal fluid of humans, but its functions are not known. ...
In kinetic competition experiments using free radical-trapping agents, the capacity of IPA to
scavenge hydroxyl radicals exceeded that of melatonin, an indoleamine considered to be
the most potent naturally occurring scavenger of free radicals. In contrast with other
antioxidants, IPA was not converted to reactive intermediates with pro-oxidant activity."
81. Hopper, Christopher P.; De La Cruz, Ladie Kimberly; Lyles, Kristin V.; Wareham, Lauren K.;
Gilbert, Jack A.; Eichenbaum, Zehava; Magierowski, Marcin; Poole, Robert K.; Wollborn,
Jakob; Wang, Binghe (2020-12-23). "Role of Carbon Monoxide in Host–Gut Microbiome
Communication". Chemical Reviews. 120 (24): 13273–13311.
doi:10.1021/acs.chemrev.0c00586 (https://doi.org/10.1021%2Facs.chemrev.0c00586).
ISSN 0009-2665 (https://www.worldcat.org/issn/0009-2665). PMID 33089988 (https://pubme
d.ncbi.nlm.nih.gov/33089988). S2CID 224824871 (https://api.semanticscholar.org/CorpusID:
224824871).
82. Rajilić-Stojanović, Mirjana; De Vos, Willem M (2014). "The first 1000 cultured species of the
human gastrointestinal microbiota" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC426207
2). FEMS Microbiology Reviews. 38 (5): 996–1047. doi:10.1111/1574-6976.12075 (https://do
i.org/10.1111%2F1574-6976.12075). PMC 4262072 (https://www.ncbi.nlm.nih.gov/pmc/articl
es/PMC4262072). PMID 24861948 (https://pubmed.ncbi.nlm.nih.gov/24861948).
83. Hill, M. J. (March 1997). "Intestinal flora and endogenous vitamin synthesis" (https://pubmed.
ncbi.nlm.nih.gov/9167138/). European Journal of Cancer Prevention. 6 (Suppl 1): S43–45.
doi:10.1097/00008469-199703001-00009 (https://doi.org/10.1097%2F00008469-199703001
-00009). ISSN 0959-8278 (https://www.worldcat.org/issn/0959-8278). PMID 9167138 (https://
pubmed.ncbi.nlm.nih.gov/9167138). S2CID 8740364 (https://api.semanticscholar.org/Corpus
ID:8740364).
84. "The Microbiome" (https://now.tufts.edu/articles/microbiome). Tufts Now. 2013-09-17.
Retrieved 2020-12-09.
85. Moraïs, Sarah; Winkler, Sarah; Zorea, Alvah; Levin, Liron; Nagies, Falk S. P.; Kapust, Nils;
Lamed, Eva; Artan-Furman, Avital; Bolam, David N.; Yadav, Madhav P.; Bayer, Edward A.;
Martin, William F.; Mizrahi, Itzhak (2024-03-15). "Cryptic diversity of cellulose-degrading gut
bacteria in industrialized humans" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7615765).
Science. 383 (6688): eadj9223. doi:10.1126/science.adj9223 (https://doi.org/10.1126%2Fsci
ence.adj9223). ISSN 0036-8075 (https://www.worldcat.org/issn/0036-8075). PMC 7615765
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7615765). PMID 38484069 (https://pubmed.n
cbi.nlm.nih.gov/38484069).
86. ElRakaiby M, Dutilh BE, Rizkallah MR, Boleij A, Cole JN, Aziz RK (July 2014).
"Pharmacomicrobiomics: the impact of human microbiome variations on systems
pharmacology and personalized therapeutics" (https://www.ncbi.nlm.nih.gov/pmc/articles/PM
C4086029). Omics. 18 (7): 402–414. doi:10.1089/omi.2014.0018 (https://doi.org/10.1089%2
Fomi.2014.0018). PMC 4086029 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086029).
PMID 24785449 (https://pubmed.ncbi.nlm.nih.gov/24785449).
87. Cho I, Blaser MJ (March 2012). "The human microbiome: at the interface of health and
disease" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418802). Nature Reviews.
Genetics. 13 (4): 260–270. doi:10.1038/nrg3182 (https://doi.org/10.1038%2Fnrg3182).
PMC 3418802 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418802). PMID 22411464 (h
ttps://pubmed.ncbi.nlm.nih.gov/22411464). "The composition of the microbiome varies by
anatomical site (Figure 1). The primary determinant of community composition is anatomical
location: interpersonal variation is substantial23,24 and is higher than the temporal
variability seen at most sites in a single individual25."
88. Hutter T, Gimbert C, Bouchard F, Lapointe FJ (2015). "Being human is a gut feeling" (https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC4359430). Microbiome. 3: 9. doi:10.1186/s40168-
015-0076-7 (https://doi.org/10.1186%2Fs40168-015-0076-7). PMC 4359430 (https://www.nc
bi.nlm.nih.gov/pmc/articles/PMC4359430). PMID 25774294 (https://pubmed.ncbi.nlm.nih.go
v/25774294).
89. Kumar K, Dhoke GV, Sharma AK, Jaiswal SK, Sharma VK (January 2019). "Mechanistic
elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota
using molecular dynamics simulations". Journal of Cellular Biochemistry. 120 (7): 11206–
11215. doi:10.1002/jcb.28396 (https://doi.org/10.1002%2Fjcb.28396). PMID 30701587 (http
s://pubmed.ncbi.nlm.nih.gov/30701587). S2CID 73413138 (https://api.semanticscholar.org/C
orpusID:73413138).
90. Sousa, Tiago; Paterson, Ronnie; Moore, Vanessa; Carlsson, Anders; Abrahamsson, Bertil;
Basit, Abdul W (2008). "The gastrointestinal microbiota as a site for the biotransformation of
drugs". International Journal of Pharmaceutics. 363 (1–2): 1–25.
doi:10.1016/j.ijpharm.2008.07.009 (https://doi.org/10.1016%2Fj.ijpharm.2008.07.009).
PMID 18682282 (https://pubmed.ncbi.nlm.nih.gov/18682282).
91. Haiser, H. J; Gootenberg, D. B; Chatman, K; Sirasani, G; Balskus, E. P; Turnbaugh, P. J
(2013). "Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium
Eggerthella lenta" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736355). Science. 341
(6143): 295–298. Bibcode:2013Sci...341..295H (https://ui.adsabs.harvard.edu/abs/2013Sci...
341..295H). doi:10.1126/science.1235872 (https://doi.org/10.1126%2Fscience.1235872).
PMC 3736355 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736355). PMID 23869020 (h
ttps://pubmed.ncbi.nlm.nih.gov/23869020).
92. Koppel, Nitzan; Maini Rekdal, Vayu; Balskus, Emily P. (2017-06-23). "Chemical
transformation of xenobiotics by the human gut microbiota" (https://www.ncbi.nlm.nih.gov/pm
c/articles/PMC5534341). Science. 356 (6344). doi:10.1126/science.aag2770 (https://doi.org/
10.1126%2Fscience.aag2770). ISSN 0036-8075 (https://www.worldcat.org/issn/0036-8075).
PMC 5534341 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534341). PMID 28642381 (h
ttps://pubmed.ncbi.nlm.nih.gov/28642381).
93. Spanogiannopoulos, Peter; Bess, Elizabeth N.; Carmody, Rachel N.; Turnbaugh, Peter J.
(2016-03-14). "The microbial pharmacists within us: a metagenomic view of xenobiotic
metabolism" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243131). Nature Reviews
Microbiology. 14 (5): 273–287. doi:10.1038/nrmicro.2016.17 (https://doi.org/10.1038%2Fnrmi
cro.2016.17). ISSN 1740-1526 (https://www.worldcat.org/issn/1740-1526). PMC 5243131 (htt
ps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243131). PMID 26972811 (https://pubmed.ncb
i.nlm.nih.gov/26972811).
94. Maini Rekdal, Vayu; Bess, Elizabeth N.; Bisanz, Jordan E.; Turnbaugh, Peter J.; Balskus,
Emily P. (2019-06-14). "Discovery and inhibition of an interspecies gut bacterial pathway for
Levodopa metabolism" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745125). Science.
364 (6445). doi:10.1126/science.aau6323 (https://doi.org/10.1126%2Fscience.aau6323).
ISSN 0036-8075 (https://www.worldcat.org/issn/0036-8075). PMC 7745125 (https://www.ncb
i.nlm.nih.gov/pmc/articles/PMC7745125). PMID 31196984 (https://pubmed.ncbi.nlm.nih.gov/
31196984).
95. Dempsey, Joseph L.; Cui, Julia Yue (2019-10-19). "Microbiome Is a Functional Modifier of
P450 Drug Metabolism" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731899). Current
Pharmacology Reports. 5 (6): 481–490. doi:10.1007/s40495-019-00200-w (https://doi.org/10.
1007%2Fs40495-019-00200-w). ISSN 2198-641X (https://www.worldcat.org/issn/2198-641
X). PMC 7731899 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731899).
PMID 33312848 (https://pubmed.ncbi.nlm.nih.gov/33312848).
96. Boerner, Udo; Abbott, Seth; Roe, Robert L. (January 1975). "The Metabolism of Morphine
and Heroin in Man". Drug Metabolism Reviews. 4 (1): 39–73.
doi:10.3109/03602537508993748 (https://doi.org/10.3109%2F03602537508993748).
ISSN 0360-2532 (https://www.worldcat.org/issn/0360-2532). PMID 1204496 (https://pubmed.
ncbi.nlm.nih.gov/1204496).
97. Dobkin, Jay F.; Saha, Jnan R.; Butler, Vincent P.; Neu, Harold C.; Lindenbaum, John (1983-
04-15). "Digoxin-Inactivating Bacteria: Identification in Human Gut Flora". Science. 220
(4594): 325–327. doi:10.1126/science.6836275 (https://doi.org/10.1126%2Fscience.683627
5). ISSN 0036-8075 (https://www.worldcat.org/issn/0036-8075). PMID 6836275 (https://pubm
ed.ncbi.nlm.nih.gov/6836275).
98. Sahota, S. S.; Bramley, P. M.; Menzies, I. S. (1982-02-01). "The Fermentation of Lactulose by
Colonic Bacteria" (https://doi.org/10.1099%2F00221287-128-2-319). Microbiology. 128 (2):
319–325. doi:10.1099/00221287-128-2-319 (https://doi.org/10.1099%2F00221287-128-2-31
9). ISSN 1350-0872 (https://www.worldcat.org/issn/1350-0872). PMID 6804597 (https://pubm
ed.ncbi.nlm.nih.gov/6804597).
99. Yoo, Dae-Hyoung; Kim, In Sook; Van Le, Thi Kim; Jung, Il-Hoon; Yoo, Hye Hyun; Kim, Dong-
Hyun (2014-06-19). "Gut Microbiota-Mediated Drug Interactions between Lovastatin and
Antibiotics". Drug Metabolism and Disposition. 42 (9): 1508–1513.
doi:10.1124/dmd.114.058354 (https://doi.org/10.1124%2Fdmd.114.058354). ISSN 0090-
9556 (https://www.worldcat.org/issn/0090-9556). PMID 24947972 (https://pubmed.ncbi.nlm.n
ih.gov/24947972). S2CID 7524335 (https://api.semanticscholar.org/CorpusID:7524335).
100. Haiser, Henry J.; Gootenberg, David B.; Chatman, Kelly; Sirasani, Gopal; Balskus, Emily P.;
Turnbaugh, Peter J. (2013-07-19). "Predicting and Manipulating Cardiac Drug Inactivation by
the Human Gut Bacterium Eggerthella lenta" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC
3736355). Science. 341 (6143): 295–298. Bibcode:2013Sci...341..295H (https://ui.adsabs.ha
rvard.edu/abs/2013Sci...341..295H). doi:10.1126/science.1235872 (https://doi.org/10.1126%
2Fscience.1235872). ISSN 0036-8075 (https://www.worldcat.org/issn/0036-8075).
PMC 3736355 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736355). PMID 23869020 (h
ttps://pubmed.ncbi.nlm.nih.gov/23869020).
101. Parvez, Md Masud; Basit, Abdul; Jariwala, Parth B.; Gáborik, Zsuzsanna; Kis, Emese;
Heyward, Scott; Redinbo, Matthew R.; Prasad, Bhagwat (2021-06-01). "Quantitative
Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation" (https://ww
w.ncbi.nlm.nih.gov/pmc/articles/PMC8407663). Drug Metabolism and Disposition. 49 (8):
683–693. doi:10.1124/dmd.121.000476 (https://doi.org/10.1124%2Fdmd.121.000476).
ISSN 0090-9556 (https://www.worldcat.org/issn/0090-9556). PMC 8407663 (https://www.ncb
i.nlm.nih.gov/pmc/articles/PMC8407663). PMID 34074730 (https://pubmed.ncbi.nlm.nih.gov/
34074730).
102. Sousa, Tiago; Paterson, Ronnie; Moore, Vanessa; Carlsson, Anders; Abrahamsson, Bertil;
Basit, Abdul W. (November 2008). "The gastrointestinal microbiota as a site for the
biotransformation of drugs". International Journal of Pharmaceutics. 363 (1–2): 1–25.
doi:10.1016/j.ijpharm.2008.07.009 (https://doi.org/10.1016%2Fj.ijpharm.2008.07.009).
ISSN 0378-5173 (https://www.worldcat.org/issn/0378-5173). PMID 18682282 (https://pubme
d.ncbi.nlm.nih.gov/18682282).
103. Koppel, Nitzan; Bisanz, Jordan E; Pandelia, Maria-Eirini; Turnbaugh, Peter J; Balskus, Emily
P (2018-05-15). Ley, Ruth Emily (ed.). "Discovery and characterization of a prevalent human
gut bacterial enzyme sufficient for the inactivation of a family of plant toxins" (https://www.ncb
i.nlm.nih.gov/pmc/articles/PMC5953540). eLife. 7: e33953. doi:10.7554/eLife.33953 (https://d
oi.org/10.7554%2FeLife.33953). ISSN 2050-084X (https://www.worldcat.org/issn/2050-084
X). PMC 5953540 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953540).
PMID 29761785 (https://pubmed.ncbi.nlm.nih.gov/29761785).
104. Alexander, James L.; Wilson, Ian D.; Teare, Julian; Marchesi, Julian R.; Nicholson, Jeremy
K.; Kinross, James M. (2017-03-08). "Gut microbiota modulation of chemotherapy efficacy
and toxicity" (https://orca.cardiff.ac.uk/id/eprint/100186/). Nature Reviews Gastroenterology &
Hepatology. 14 (6): 356–365. doi:10.1038/nrgastro.2017.20 (https://doi.org/10.1038%2Fnrga
stro.2017.20). hdl:10044/1/77636 (https://hdl.handle.net/10044%2F1%2F77636).
ISSN 1759-5045 (https://www.worldcat.org/issn/1759-5045). PMID 28270698 (https://pubme
d.ncbi.nlm.nih.gov/28270698). S2CID 9654170 (https://api.semanticscholar.org/CorpusID:96
54170).
105. Brandi, Giovanni; Dabard, Jean; Raibaud, Pierre; Di Battista, Monica; Bridonneau, Chantal;
Pisi, Anna Maria; Morselli Labate, Antonio Maria; Pantaleo, Maria Abbondanza; De Vivo,
Antonello; Biasco, Guido (2006-02-15). "Intestinal microflora and digestive toxicity of
irinotecan in mice". Clinical Cancer Research. 12 (4): 1299–1307. doi:10.1158/1078-
0432.ccr-05-0750 (https://doi.org/10.1158%2F1078-0432.ccr-05-0750). ISSN 1078-0432 (htt
ps://www.worldcat.org/issn/1078-0432). PMID 16489087 (https://pubmed.ncbi.nlm.nih.gov/16
489087). S2CID 26655779 (https://api.semanticscholar.org/CorpusID:26655779).
106. Koh, Ara; De Vadder, Filipe; Kovatcheva-Datchary, Petia; Bäckhed, Fredrik (June 2016).
"From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial
Metabolites" (https://doi.org/10.1016%2Fj.cell.2016.05.041). Cell. 165 (6): 1332–1345.
doi:10.1016/j.cell.2016.05.041 (https://doi.org/10.1016%2Fj.cell.2016.05.041). ISSN 0092-
8674 (https://www.worldcat.org/issn/0092-8674). PMID 27259147 (https://pubmed.ncbi.nlm.n
ih.gov/27259147). S2CID 8562345 (https://api.semanticscholar.org/CorpusID:8562345).
107. Konopelski, Piotr; Ufnal, Marcin (2018-09-14). "Indoles - Gut Bacteria Metabolites of
Tryptophan with Pharmacotherapeutic Potential". Current Drug Metabolism. 19 (10): 883–
890. doi:10.2174/1389200219666180427164731 (https://doi.org/10.2174%2F13892002196
66180427164731). ISSN 1389-2002 (https://www.worldcat.org/issn/1389-2002).
PMID 29708069 (https://pubmed.ncbi.nlm.nih.gov/29708069). S2CID 13979774 (https://api.s
emanticscholar.org/CorpusID:13979774).
108. Collins, Stephanie L.; Stine, Jonathan G.; Bisanz, Jordan E.; Okafor, C. Denise; Patterson,
Andrew D. (2022-10-17). "Bile acids and the gut microbiota: metabolic interactions and
impacts on disease". Nature Reviews Microbiology. 21 (4): 236–247. doi:10.1038/s41579-
022-00805-x (https://doi.org/10.1038%2Fs41579-022-00805-x). ISSN 1740-1526 (https://ww
w.worldcat.org/issn/1740-1526). PMID 36253479 (https://pubmed.ncbi.nlm.nih.gov/3625347
9). S2CID 252970168 (https://api.semanticscholar.org/CorpusID:252970168).
109. Yang, Wenjing; Yu, Tianming; Huang, Xiangsheng; Bilotta, Anthony J.; Xu, Leiqi; Lu, Yao;
Sun, Jiaren; Pan, Fan; Zhou, Jia; Zhang, Wenbo; Yao, Suxia; Maynard, Craig L.; Singh,
Nagendra; Dann, Sara M.; Liu, Zhanju (2020-09-08). "Intestinal microbiota-derived short-
chain fatty acids regulation of immune cell IL-22 production and gut immunity" (https://www.n
cbi.nlm.nih.gov/pmc/articles/PMC7478978). Nature Communications. 11 (1): 4457.
Bibcode:2020NatCo..11.4457Y (https://ui.adsabs.harvard.edu/abs/2020NatCo..11.4457Y).
doi:10.1038/s41467-020-18262-6 (https://doi.org/10.1038%2Fs41467-020-18262-6).
ISSN 2041-1723 (https://www.worldcat.org/issn/2041-1723). PMC 7478978 (https://www.ncb
i.nlm.nih.gov/pmc/articles/PMC7478978). PMID 32901017 (https://pubmed.ncbi.nlm.nih.gov/
32901017).
110. Murugesan, Selvasankar; Nirmalkar, Khemlal; Hoyo-Vadillo, Carlos; García-Espitia, Matilde;
Ramírez-Sánchez, Daniela; García-Mena, Jaime (2017-12-02). "Gut microbiome production
of short-chain fatty acids and obesity in children". European Journal of Clinical Microbiology
& Infectious Diseases. 37 (4): 621–625. doi:10.1007/s10096-017-3143-0 (https://doi.org/10.1
007%2Fs10096-017-3143-0). ISSN 0934-9723 (https://www.worldcat.org/issn/0934-9723).
PMID 29196878 (https://pubmed.ncbi.nlm.nih.gov/29196878). S2CID 254132108 (https://api.
semanticscholar.org/CorpusID:254132108).
111. Thanissery, Rajani; Winston, Jenessa A.; Theriot, Casey M. (June 2017). "Inhibition of spore
germination, growth, and toxin activity of clinically relevant C. difficile strains by gut
microbiota derived secondary bile acids" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC546
6893). Anaerobe. 45: 86–100. doi:10.1016/j.anaerobe.2017.03.004 (https://doi.org/10.1016%
2Fj.anaerobe.2017.03.004). ISSN 1075-9964 (https://www.worldcat.org/issn/1075-9964).
PMC 5466893 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466893). PMID 28279860 (h
ttps://pubmed.ncbi.nlm.nih.gov/28279860).
112. Jones, Brian V.; Begley, Máire; Hill, Colin; Gahan, Cormac G. M.; Marchesi, Julian R. (2008-
09-09). "Functional and comparative metagenomic analysis of bile salt hydrolase activity in
the human gut microbiome" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533232).
Proceedings of the National Academy of Sciences. 105 (36): 13580–13585.
Bibcode:2008PNAS..10513580J (https://ui.adsabs.harvard.edu/abs/2008PNAS..10513580
J). doi:10.1073/pnas.0804437105 (https://doi.org/10.1073%2Fpnas.0804437105).
ISSN 0027-8424 (https://www.worldcat.org/issn/0027-8424). PMC 2533232 (https://www.ncb
i.nlm.nih.gov/pmc/articles/PMC2533232). PMID 18757757 (https://pubmed.ncbi.nlm.nih.gov/
18757757).
113. Cao H, Xu M, Dong W, Deng B, Wang S, Zhang Y, Wang S, Luo S, Wang W, Qi Y, Gao J,
Cao X, Yan F, Wang B (June 2017). "Secondary bile acid-induced dysbiosis promotes
intestinal carcinogenesis" (https://doi.org/10.1002%2Fijc.30643). International Journal of
Cancer. 140 (11): 2545–2556. doi:10.1002/ijc.30643 (https://doi.org/10.1002%2Fijc.30643).
PMID 28187526 (https://pubmed.ncbi.nlm.nih.gov/28187526).
114. Bernstein H, Bernstein C (January 2023). "Bile acids as carcinogens in the colon and at
other sites in the gastrointestinal system" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC99
89147). Experimental Biology and Medicine. 248 (1): 79–89.
doi:10.1177/15353702221131858 (https://doi.org/10.1177%2F15353702221131858).
PMC 9989147 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989147). PMID 36408538 (h
ttps://pubmed.ncbi.nlm.nih.gov/36408538).
115. Mayer, E. A; Knight, R; Mazmanian, S. K; Cryan, J. F; Tillisch, K (2014). "Gut Microbes and
the Brain: Paradigm Shift in Neuroscience" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4
228144). Journal of Neuroscience. 34 (46): 15490–15496. doi:10.1523/JNEUROSCI.3299-
14.2014 (https://doi.org/10.1523%2FJNEUROSCI.3299-14.2014). PMC 4228144 (https://ww
w.ncbi.nlm.nih.gov/pmc/articles/PMC4228144). PMID 25392516 (https://pubmed.ncbi.nlm.ni
h.gov/25392516).
116. Dinan, Timothy G; Cryan, John F (2015). "The impact of gut microbiota on brain and
behaviour". Current Opinion in Clinical Nutrition and Metabolic Care. 18 (6): 552–558.
doi:10.1097/MCO.0000000000000221 (https://doi.org/10.1097%2FMCO.000000000000022
1). PMID 26372511 (https://pubmed.ncbi.nlm.nih.gov/26372511). S2CID 21424690 (https://a
pi.semanticscholar.org/CorpusID:21424690).
117. Carman, Robert J.; Simon, Mary Alice; Fernández, Haydée; Miller, Margaret A.;
Bartholomew, Mary J. (2004). "Ciprofloxacin at low levels disrupts colonization resistance of
human fecal microflora growing in chemostats". Regulatory Toxicology and Pharmacology.
40 (3): 319–326. doi:10.1016/j.yrtph.2004.08.005 (https://doi.org/10.1016%2Fj.yrtph.2004.08.
005). PMID 15546686 (https://pubmed.ncbi.nlm.nih.gov/15546686).
118. Hvas, Christian Lodberg; Baunwall, Simon Mark Dahl; Erikstrup, Christian (2020-07-01).
"Faecal microbiota transplantation: A life-saving therapy challenged by commercial claims
for exclusivity" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334803). eClinicalMedicine.
24: 100436. doi:10.1016/j.eclinm.2020.100436 (https://doi.org/10.1016%2Fj.eclinm.2020.10
0436). ISSN 2589-5370 (https://www.worldcat.org/issn/2589-5370). PMC 7334803 (https://w
ww.ncbi.nlm.nih.gov/pmc/articles/PMC7334803). PMID 32642633 (https://pubmed.ncbi.nlm.
nih.gov/32642633).
119. Brandt, Lawrence J.; Borody, Thomas Julius; Campbell, Jordana (2011). "Endoscopic Fecal
Microbiota Transplantation" (https://doi.org/10.1097%2FMCG.0b013e3182257d4f). Journal
of Clinical Gastroenterology. 45 (8): 655–657. doi:10.1097/MCG.0b013e3182257d4f (https://
doi.org/10.1097%2FMCG.0b013e3182257d4f). PMID 21716124 (https://pubmed.ncbi.nlm.ni
h.gov/21716124). S2CID 2508836 (https://api.semanticscholar.org/CorpusID:2508836).
120. Knight, DJW; Girling, KJ (2003). "Gut flora in health and disease" (https://doi.org/10.1016%2
FS0140-6736%2803%2913438-1). The Lancet. 361 (9371): 512–519. doi:10.1016/S0140-
6736(03)13438-1 (https://doi.org/10.1016%2FS0140-6736%2803%2913438-1).
PMID 12781578 (https://pubmed.ncbi.nlm.nih.gov/12781578). S2CID 40683723 (https://api.s
emanticscholar.org/CorpusID:40683723).
121. Cho, I.; Yamanishi, S.; Cox, L.; Methé, B. A.; Zavadil, J.; Li, K.; Gao, Z.; Mahana, D.; Raju, K.;
Teitler, I.; Li, H.; Alekseyenko, A. V.; Blaser, M. J. (2012). "Antibiotics in early life alter the
murine colonic microbiome and adiposity" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC35
53221). Nature. 488 (7413): 621–626. Bibcode:2012Natur.488..621C (https://ui.adsabs.harva
rd.edu/abs/2012Natur.488..621C). doi:10.1038/nature11400 (https://doi.org/10.1038%2Fnatu
re11400). PMC 3553221 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553221).
PMID 22914093 (https://pubmed.ncbi.nlm.nih.gov/22914093).
122. Schneiderhan, J; Master-Hunter, T; Locke, A (2016). "Targeting gut flora to treat and prevent
disease". The Journal of Family Practice. 65 (1): 34–38. PMID 26845162 (https://pubmed.nc
bi.nlm.nih.gov/26845162).
123. Baker, Monya (2012). "Pregnancy alters resident gut microbes" (https://doi.org/10.1038%2Fn
ature.2012.11118). Nature. doi:10.1038/nature.2012.11118 (https://doi.org/10.1038%2Fnatur
e.2012.11118). S2CID 87078157 (https://api.semanticscholar.org/CorpusID:87078157).
124. Hill, Colin; Guarner, Francisco; Reid, Gregor; Gibson, Glenn R; Merenstein, Daniel J; Pot,
Bruno; Morelli, Lorenzo; Canani, Roberto Berni; Flint, Harry J; Salminen, Seppo; Calder,
Philip C; Sanders, Mary Ellen (2014). "The International Scientific Association for Probiotics
and Prebiotics consensus statement on the scope and appropriate use of the term probiotic"
(https://doi.org/10.1038%2Fnrgastro.2014.66). Nature Reviews Gastroenterology &
Hepatology. 11 (8): 506–514. doi:10.1038/nrgastro.2014.66 (https://doi.org/10.1038%2Fnrga
stro.2014.66). hdl:2164/4189 (https://hdl.handle.net/2164%2F4189). PMID 24912386 (https://
pubmed.ncbi.nlm.nih.gov/24912386).
125. Rijkers, Ger T; De Vos, Willem M; Brummer, Robert-Jan; Morelli, Lorenzo; Corthier, Gerard;
Marteau, Philippe (2011). "Health benefits and health claims of probiotics: Bridging science
and marketing" (https://doi.org/10.1017%2FS000711451100287X). British Journal of
Nutrition. 106 (9): 1291–1296. doi:10.1017/S000711451100287X (https://doi.org/10.1017%2
FS000711451100287X). PMID 21861940 (https://pubmed.ncbi.nlm.nih.gov/21861940).
126. Hutkins, Robert W; Krumbeck, Janina A; Bindels, Laure B; Cani, Patrice D; Fahey, George;
Goh, Yong Jun; Hamaker, Bruce; Martens, Eric C; Mills, David A; Rastal, Robert A; Vaughan,
Elaine; Sanders, Mary Ellen (2016). "Prebiotics: Why definitions matter" (https://www.ncbi.nl
m.nih.gov/pmc/articles/PMC4744122). Current Opinion in Biotechnology. 37: 1–7.
doi:10.1016/j.copbio.2015.09.001 (https://doi.org/10.1016%2Fj.copbio.2015.09.001).
PMC 4744122 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744122). PMID 26431716 (h
ttps://pubmed.ncbi.nlm.nih.gov/26431716).
127. Pandey, Kavita. R; Naik, Suresh. R; Vakil, Babu. V (2015). "Probiotics, prebiotics and
synbiotics- a review" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648921). Journal of
Food Science and Technology. 52 (12): 7577–7587. doi:10.1007/s13197-015-1921-1 (http
s://doi.org/10.1007%2Fs13197-015-1921-1). PMC 4648921 (https://www.ncbi.nlm.nih.gov/p
mc/articles/PMC4648921). PMID 26604335 (https://pubmed.ncbi.nlm.nih.gov/26604335).
128. Broeckx, Géraldine; Vandenheuvel, Dieter; Claes, Ingmar J.J; Lebeer, Sarah; Kiekens, Filip
(2016). "Drying techniques of probiotic bacteria as an important step towards the
development of novel pharmabiotics" (https://repository.uantwerpen.be/docman/irua/9d9f03/
132884.pdf) (PDF). International Journal of Pharmaceutics. 505 (1–2): 303–318.
doi:10.1016/j.ijpharm.2016.04.002 (https://doi.org/10.1016%2Fj.ijpharm.2016.04.002).
hdl:10067/1328840151162165141 (https://hdl.handle.net/10067%2F132884015116216514
1). PMID 27050865 (https://pubmed.ncbi.nlm.nih.gov/27050865).
129. Sleator, Roy D; Hill, Colin (2009). "Rational Design of Improved Pharmabiotics" (https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC2742647). Journal of Biomedicine and Biotechnology.
2009: 275287. doi:10.1155/2009/275287 (https://doi.org/10.1155%2F2009%2F275287).
PMC 2742647 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742647). PMID 19753318 (h
ttps://pubmed.ncbi.nlm.nih.gov/19753318).
130. Patterson, Elaine; Cryan, John F; Fitzgerald, Gerald F; Ross, R. Paul; Dinan, Timothy G;
Stanton, Catherine (2014). "Gut microbiota, the pharmabiotics they produce and host health"
(https://doi.org/10.1017%2FS0029665114001426). Proceedings of the Nutrition Society. 73
(4): 477–489. doi:10.1017/S0029665114001426 (https://doi.org/10.1017%2FS00296651140
01426). PMID 25196939 (https://pubmed.ncbi.nlm.nih.gov/25196939).
131. "Non-prescription therapeutics for IBS: Where are we?" (https://www.gutmicrobiotaforhealth.c
om/non-prescription-therapeutics-for-ibs-where-are-we/). 30 January 2024.
132. Guandalini, Stefano; Magazzù, Giuseppe; Chiaro, Andrea; La Balestra, Valeria; Di Nardo,
Giovanni; Gopalan, Sarath; Sibal, A.; Romano, Claudio; Canani, Roberto Berni; Lionetti,
Paolo; Setty, Mala (July 2010). "VSL#3 Improves Symptoms in Children with Irritable Bowel
Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Crossover Study"
(https://journals.lww.com/jpgn/Fulltext/2010/07000/VSL_3_Improves_Symptoms_in_Childre
n_With_Irritable.6.aspx). Journal of Pediatric Gastroenterology and Nutrition. 51 (1): 24–30.
doi:10.1097/MPG.0b013e3181ca4d95 (https://doi.org/10.1097%2FMPG.0b013e3181ca4d9
5). PMID 20453678 (https://pubmed.ncbi.nlm.nih.gov/20453678). S2CID 33659736 (https://a
pi.semanticscholar.org/CorpusID:33659736).
133. Ford, Alexander C; Quigley, Eamonn M M; Lacy, Brian E; Lembo, Anthony J; Saito, Yuri A;
Schiller, Lawrence R; Soffer, Edy E; Spiegel, Brennan M R; Moayyedi, Paul (2014). "Efficacy
of Prebiotics, Probiotics and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic
Constipation: Systematic Review and Meta-analysis". The American Journal of
Gastroenterology. 109 (10): 1547–1561, quiz 1546, 1562. doi:10.1038/ajg.2014.202 (https://d
oi.org/10.1038%2Fajg.2014.202). PMID 25070051 (https://pubmed.ncbi.nlm.nih.gov/250700
51). S2CID 205100508 (https://api.semanticscholar.org/CorpusID:205100508).
134. Dupont, Andrew; Richards; Jelinek, Katherine A; Krill, Joseph; Rahimi, Erik; Ghouri, Yezaz
(2014). "Systematic review of randomized controlled trials of probiotics, prebiotics, and
synbiotics in inflammatory bowel disease" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC42
66241). Clinical and Experimental Gastroenterology. 7: 473–487. doi:10.2147/CEG.S27530
(https://doi.org/10.2147%2FCEG.S27530). PMC 4266241 (https://www.ncbi.nlm.nih.gov/pm
c/articles/PMC4266241). PMID 25525379 (https://pubmed.ncbi.nlm.nih.gov/25525379).
135. Yu, Cheng Gong; Huang, Qin (2013). "Recent progress on the role of gut microbiota in the
pathogenesis of inflammatory bowel disease" (https://doi.org/10.1111%2F1751-2980.1208
7). Journal of Digestive Diseases. 14 (10): 513–517. doi:10.1111/1751-2980.12087 (https://d
oi.org/10.1111%2F1751-2980.12087). PMID 23848393 (https://pubmed.ncbi.nlm.nih.gov/23
848393). S2CID 26982085 (https://api.semanticscholar.org/CorpusID:26982085).
136. Levitt, Michael D.; Duane, William C. (1972-05-04). "Floating Stools – Flatus versus Fat".
New England Journal of Medicine. 286 (18): 973–975. doi:10.1056/NEJM197205042861804
(https://doi.org/10.1056%2FNEJM197205042861804). ISSN 0028-4793 (https://www.worldc
at.org/issn/0028-4793). PMID 5015442 (https://pubmed.ncbi.nlm.nih.gov/5015442).
137. Aalam, Syed Mohammed Musheer; Crasta, Daphne Norma; Roy, Pooja; Miller, A. Lee;
Gamb, Scott I.; Johnson, Stephen; Till, Lisa M.; Chen, Jun; Kashyap, Purna; Kannan,
Nagarajan (2022-10-27). "Genesis of fecal floatation is causally linked to gut microbial
colonization in mice" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613883). Scientific
Reports. 12 (1): 18109. Bibcode:2022NatSR..1218109A (https://ui.adsabs.harvard.edu/abs/2
022NatSR..1218109A). doi:10.1038/s41598-022-22626-x (https://doi.org/10.1038%2Fs4159
8-022-22626-x). ISSN 2045-2322 (https://www.worldcat.org/issn/2045-2322). PMC 9613883
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613883). PMID 36302811 (https://pubmed.n
cbi.nlm.nih.gov/36302811).
138. Maier, Lisa; Pruteanu, Mihaela; Kuhn, Michael; Zeller, Georg; Telzerow, Anja; Anderson,
Exene Erin; Brochado, Ana Rita; Fernandez, Keith Conrad; Dose, Hitomi; Mori, Hirotada;
Patil, Kiran Raosaheb; Bork, Peer; Typas, Athanasios (2018). "Extensive impact of non-
antibiotic drugs on human gut bacteria" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108
420). Nature. 555 (7698): 623–628. Bibcode:2018Natur.555..623M (https://ui.adsabs.harvar
d.edu/abs/2018Natur.555..623M). doi:10.1038/nature25979 (https://doi.org/10.1038%2Fnatur
e25979). PMC 6108420 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108420).
PMID 29555994 (https://pubmed.ncbi.nlm.nih.gov/29555994).
139. Clauss, Matthieu; Gérard, Philippe; Mosca, Alexis; Leclerc, Marion (2021). "Interplay
Between Exercise and Gut Microbiome in the Context of Human Health and Performance" (h
ttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222532). Frontiers in Nutrition. 8: 637010.
doi:10.3389/fnut.2021.637010 (https://doi.org/10.3389%2Ffnut.2021.637010). PMC 8222532
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222532). PMID 34179053 (https://pubmed.n
cbi.nlm.nih.gov/34179053).
140. Kamboj, AK; Cotter, TG; Oxentenko, AS (2017). "Helicobacter pylori: The Past, Present, and
Future in Management" (https://www.mayoclinicproceedings.org/article/S0025-6196(17)300
68-X/fulltext). Mayo Clinic Proceedings. 92 (4): 599–604. doi:10.1016/j.mayocp.2016.11.017
(https://doi.org/10.1016%2Fj.mayocp.2016.11.017). ISSN 0025-6196 (https://www.worldcat.o
rg/issn/0025-6196). PMID 28209367 (https://pubmed.ncbi.nlm.nih.gov/28209367).
141. "Peptic ulcer disease" (https://www.hopkinsmedicine.org/gastroenterology_hepatology/_pdf
s/esophagus_stomach/peptic_ulcer_disease.pdf) (PDF). The Johns Hopkins University
School of Medicine. 2013. Retrieved 21 October 2020.
142. Burisch, Johan; Jess, Tine; Martinato, Matteo; Lakatos, Peter L (2013). "The burden of
inflammatory bowel disease in Europe" (https://doi.org/10.1016%2Fj.crohns.2013.01.010).
Journal of Crohn's and Colitis. 7 (4): 322–337. doi:10.1016/j.crohns.2013.01.010 (https://doi.
org/10.1016%2Fj.crohns.2013.01.010). PMID 23395397 (https://pubmed.ncbi.nlm.nih.gov/23
395397).
143. Blandino, G; Inturri, R; Lazzara, F; Di Rosa, M; Malaguarnera, L (2016). "Impact of gut
microbiota on diabetes mellitus". Diabetes & Metabolism. 42 (5): 303–315.
doi:10.1016/j.diabet.2016.04.004 (https://doi.org/10.1016%2Fj.diabet.2016.04.004).
PMID 27179626 (https://pubmed.ncbi.nlm.nih.gov/27179626).
144. Boulangé, Claire L; Neves, Ana Luisa; Chilloux, Julien; Nicholson, Jeremy K; Dumas, Marc-
Emmanuel (2016). "Impact of the gut microbiota on inflammation, obesity, and metabolic
disease" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839080). Genome Medicine. 8 (1):
42. doi:10.1186/s13073-016-0303-2 (https://doi.org/10.1186%2Fs13073-016-0303-2).
PMC 4839080 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839080). PMID 27098727 (h
ttps://pubmed.ncbi.nlm.nih.gov/27098727).
145. Arrieta, Marie-Claire; Stiemsma, Leah T; Dimitriu, Pedro A; Thorson, Lisa; Russell, Shannon;
Yurist-Doutsch, Sophie; Kuzeljevic, Boris; Gold, Matthew J; Britton, Heidi M; Lefebvre, Diana
L; Subbarao, Padmaja; Mandhane, Piush; Becker, Allan; McNagny, Kelly M; Sears, Malcolm
R; Kollmann, Tobias; Mohn, William W; Turvey, Stuart E; Brett Finlay, B (2015). "Early
infancy microbial and metabolic alterations affect risk of childhood asthma" (https://doi.org/1
0.1126%2Fscitranslmed.aab2271). Science Translational Medicine. 7 (307): 307ra152.
doi:10.1126/scitranslmed.aab2271 (https://doi.org/10.1126%2Fscitranslmed.aab2271).
PMID 26424567 (https://pubmed.ncbi.nlm.nih.gov/26424567). S2CID 206687974 (https://api.
semanticscholar.org/CorpusID:206687974).
146. Stiemsma, Leah T; Turvey, Stuart E (2017). "Asthma and the microbiome: Defining the critical
window in early life" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217603). Allergy,
Asthma & Clinical Immunology. 13: 3. doi:10.1186/s13223-016-0173-6 (https://doi.org/10.11
86%2Fs13223-016-0173-6). PMC 5217603 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC
5217603). PMID 28077947 (https://pubmed.ncbi.nlm.nih.gov/28077947).
147. Ipci, Kagan; Altıntoprak, Niyazi; Muluk, Nuray Bayar; Senturk, Mehmet; Cingi, Cemal (2016).
"The possible mechanisms of the human microbiome in allergic diseases". European
Archives of Oto-Rhino-Laryngology. 274 (2): 617–626. doi:10.1007/s00405-016-4058-6 (http
s://doi.org/10.1007%2Fs00405-016-4058-6). PMID 27115907 (https://pubmed.ncbi.nlm.nih.g
ov/27115907). S2CID 27328940 (https://api.semanticscholar.org/CorpusID:27328940).
148. Mariño, Eliana; Richards, James L.; McLeod, Keiran H.; et al. (May 2017). "Gut microbial
metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes" (h
ttps://www.nature.com/articles/ni.3713). Nature Immunology. 18 (5): 552–562.
doi:10.1038/ni.3713 (https://doi.org/10.1038%2Fni.3713). ISSN 1529-2916 (https://www.worl
dcat.org/issn/1529-2916). PMID 28346408 (https://pubmed.ncbi.nlm.nih.gov/28346408).
S2CID 30078908 (https://api.semanticscholar.org/CorpusID:30078908).
149. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (May
2006). "Reciprocal developmental pathways for the generation of pathogenic effector TH17
and regulatory T cells". Nature. 441 (7090): 235–238. Bibcode:2006Natur.441..235B.
doi:10.1038/nature04753. PMID 16648838.
150. Säemann, Marcus D.; Böhmig, Georg A.; Österreicher, Christoph H.; et al. (December 2000).
"Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12
and up-regulation of IL-10 production" (https://doi.org/10.1096%2Ffj.00-0359fje). The FASEB
Journal. 14 (15): 2380–2382. doi:10.1096/fj.00-0359fje (https://doi.org/10.1096%2Ffj.00-035
9fje). ISSN 0892-6638 (https://www.worldcat.org/issn/0892-6638). PMID 11024006 (https://p
ubmed.ncbi.nlm.nih.gov/11024006). S2CID 41553220 (https://api.semanticscholar.org/Corpu
sID:41553220).
151. Gao, Z; Yin, J; Zhang, J; Ward, R. E; Martin, R. J; Lefevre, M; Cefalu, W. T; Ye, J (2009).
"Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice" (https://ww
w.ncbi.nlm.nih.gov/pmc/articles/PMC2699871). Diabetes. 58 (7): 1509–1517.
doi:10.2337/db08-1637 (https://doi.org/10.2337%2Fdb08-1637). PMC 2699871 (https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC2699871). PMID 19366864 (https://pubmed.ncbi.nlm.nih.g
ov/19366864).
152. Mazidi, Mohsen; Rezaie, Peyman; Kengne, Andre Pascal; Mobarhan, Majid Ghayour; Ferns,
Gordon A (2016). "Gut microbiome and metabolic syndrome". Diabetes & Metabolic
Syndrome: Clinical Research & Reviews. 10 (2): S150–157. doi:10.1016/j.dsx.2016.01.024
(https://doi.org/10.1016%2Fj.dsx.2016.01.024). PMID 26916014 (https://pubmed.ncbi.nlm.ni
h.gov/26916014).
153. Chen, Xiao; d'Souza, Roshan; Hong, Seong-Tshool (2013). "The role of gut microbiota in the
gut-brain axis: Current challenges and perspectives" (https://www.ncbi.nlm.nih.gov/pmc/articl
es/PMC4875553). Protein & Cell. 4 (6): 403–414. doi:10.1007/s13238-013-3017-x (https://do
i.org/10.1007%2Fs13238-013-3017-x). PMC 4875553 (https://www.ncbi.nlm.nih.gov/pmc/arti
cles/PMC4875553). PMID 23686721 (https://pubmed.ncbi.nlm.nih.gov/23686721).
154. Moeller, Andrew H.; Li, Yingying; Ngole, Eitel Mpoudi; Ahuka-Mundeke, Steve; Lonsdorf,
Elizabeth V.; Pusey, Anne E.; Peeters, Martine; Hahn, Beatrice H.; Ochman, Howard (2014-
11-18). "Rapid changes in the gut microbiome during human evolution" (https://www.ncbi.nl
m.nih.gov/pmc/articles/PMC4246287). Proceedings of the National Academy of Sciences.
111 (46): 16431–16435. Bibcode:2014PNAS..11116431M (https://ui.adsabs.harvard.edu/ab
s/2014PNAS..11116431M). doi:10.1073/pnas.1419136111 (https://doi.org/10.1073%2Fpna
s.1419136111). ISSN 0027-8424 (https://www.worldcat.org/issn/0027-8424). PMC 4246287
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246287). PMID 25368157 (https://pubmed.n
cbi.nlm.nih.gov/25368157).
155. Brune, A. (2014). "Symbiotic digestion of lignocellulose in termite guts". Nature Reviews
Microbiology. 12 (3): 168–180. doi:10.1038/nrmicro3182 (https://doi.org/10.1038%2Fnrmicro
3182). PMID 24487819 (https://pubmed.ncbi.nlm.nih.gov/24487819). S2CID 5220210 (http
s://api.semanticscholar.org/CorpusID:5220210).
156. Dietrich, C.; Köhler, T.; Brune, A. (2014). "The cockroach origin of the termite gut microbiota:
patterns in bacterial community structure reflect major evolutionary events" (https://www.ncbi.
nlm.nih.gov/pmc/articles/PMC3993134). Applied and Environmental Microbiology. 80 (7):
2261–2269. Bibcode:2014ApEnM..80.2261D (https://ui.adsabs.harvard.edu/abs/2014ApEn
M..80.2261D). doi:10.1128/AEM.04206-13 (https://doi.org/10.1128%2FAEM.04206-13).
PMC 3993134 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993134). PMID 24487532 (h
ttps://pubmed.ncbi.nlm.nih.gov/24487532).
157. Mikaelyan, A.; Dietrich, C.; Köhler, T.; Poulsen, M.; Sillam-Dussès, D.; Brune, A. (2015). "Diet
is the primary determinant of bacterial community structure in the guts of higher termites".
Molecular Ecology. 24 (20): 5824–5895. Bibcode:2015MolEc..24.5284M (https://ui.adsabs.h
arvard.edu/abs/2015MolEc..24.5284M). doi:10.1111/mec.13376 (https://doi.org/10.1111%2F
mec.13376). PMID 26348261 (https://pubmed.ncbi.nlm.nih.gov/26348261).
S2CID 206182668 (https://api.semanticscholar.org/CorpusID:206182668).
158. Mikaelyan, A.; Thompson, C.; Hofer, M.; Brune, A. (2016). "The deterministic assembly of
complex bacterial communities in germ-free cockroach guts" (https://www.ncbi.nlm.nih.gov/p
mc/articles/PMC4751828). Applied and Environmental Microbiology. 82 (4): 1256–1263.
doi:10.1128/AEM.03700-15 (https://doi.org/10.1128%2FAEM.03700-15). PMC 4751828 (http
s://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751828). PMID 26655763 (https://pubmed.ncbi.
nlm.nih.gov/26655763).
Review articles
De Preter, Vicky; Hamer, Henrike M; Windey, Karen; Verbeke, Kristin (2011). "The impact of
pre- and/or probiotics on human colonic metabolism: Does it affect human health?".
Molecular Nutrition & Food Research. 55 (1): 46–57. doi:10.1002/mnfr.201000451 (https://do
i.org/10.1002%2Fmnfr.201000451). PMID 21207512 (https://pubmed.ncbi.nlm.nih.gov/21207
512).
Maranduba, Carlos Magno da Costa; De Castro, Sandra Bertelli Ribeiro; Souza, Gustavo
Torres de; Rossato, Cristiano; Da Guia, Francisco Carlos; Valente, Maria Anete Santana;
Rettore, João Vitor Paes; Maranduba, Claudinéia Pereira; Souza, Camila Maurmann de;
Carmo, Antônio Márcio Resende do; MacEdo, Gilson Costa; Silva, Fernando de Sá (2015).
"Intestinal Microbiota as Modulators of the Immune System and Neuroimmune System:
Impact on the Host Health and Homeostasis" (https://www.ncbi.nlm.nih.gov/pmc/articles/PM
C4352473). Journal of Immunology Research. 2015: 931574. doi:10.1155/2015/931574 (http
s://doi.org/10.1155%2F2015%2F931574). PMC 4352473 (https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC4352473). PMID 25759850 (https://pubmed.ncbi.nlm.nih.gov/25759850).
Prakash, Satya; Rodes, Laetitia; Coussa-Charley, Michael; Tomaro-Duchesneau, Catherine;
Tomaro-Duchesneau, Catherine; Coussa-Charley; Rodes (2011). "Gut microbiota: Next
frontier in understanding human health and development of biotherapeutics" (https://www.nc
bi.nlm.nih.gov/pmc/articles/PMC3156250). Biologics: Targets and Therapy. 5: 71–86.
doi:10.2147/BTT.S19099 (https://doi.org/10.2147%2FBTT.S19099). PMC 3156250 (https://w
ww.ncbi.nlm.nih.gov/pmc/articles/PMC3156250). PMID 21847343 (https://pubmed.ncbi.nlm.
nih.gov/21847343).
Wu, G. D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y.-Y.; Keilbaugh, S. A.; Bewtra, M.;
Knights, D.; Walters, W. A.; Knight, R.; Sinha, R.; Gilroy, E.; Gupta, K.; Baldassano, R.;
Nessel, L.; Li, H.; Bushman, F. D.; Lewis, J.D. (2011). "Linking Long-Term Dietary Patterns
with Gut Microbial Enterotypes" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368382).
Science. 334 (6052): 105–108. Bibcode:2011Sci...334..105W (https://ui.adsabs.harvard.edu/
abs/2011Sci...334..105W). doi:10.1126/science.1208344 (https://doi.org/10.1126%2Fscienc
Further reading
e.1208344). PMC 3368382 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368382).
PMID 21885731 (https://pubmed.ncbi.nlm.nih.gov/21885731).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Gut_microbiota&oldid=1227892472"
